{"protocolSection":{"identificationModule":{"nctId":"NCT00550173","orgStudyIdInfo":{"id":"10725"},"secondaryIdInfos":[{"id":"H3E-MC-S103","type":"OTHER","domain":"Eli Lilly and Company"}],"organization":{"fullName":"Eli Lilly and Company","class":"INDUSTRY"},"briefTitle":"A Study for Non-Smoker Patients With Nonsquamous Non-Small Cell Lung Cancer","officialTitle":"A Randomized Phase 2 Study Comparing Erlotinib-Pemetrexed, Pemetrexed Alone, and Erlotinib Alone, as Second-Line Treatment for Non-Smoker Patients With Locally Advanced or Metastatic Nonsquamous Non-Small Cell Lung Cancer"},"statusModule":{"statusVerifiedDate":"2013-01","overallStatus":"COMPLETED","expandedAccessInfo":{"hasExpandedAccess":false},"startDateStruct":{"date":"2007-11"},"primaryCompletionDateStruct":{"date":"2012-01","type":"ACTUAL"},"completionDateStruct":{"date":"2012-01","type":"ACTUAL"},"studyFirstSubmitDate":"2007-10-25","studyFirstSubmitQcDate":"2007-10-25","studyFirstPostDateStruct":{"date":"2007-10-29","type":"ESTIMATED"},"resultsFirstSubmitDate":"2013-01-10","resultsFirstSubmitQcDate":"2013-01-10","resultsFirstPostDateStruct":{"date":"2013-02-13","type":"ESTIMATED"},"lastUpdateSubmitDate":"2013-01-10","lastUpdatePostDateStruct":{"date":"2013-02-13","type":"ESTIMATED"}},"sponsorCollaboratorsModule":{"responsibleParty":{"type":"SPONSOR"},"leadSponsor":{"name":"Eli Lilly and Company","class":"INDUSTRY"}},"oversightModule":{"oversightHasDmc":false},"descriptionModule":{"briefSummary":"The purpose of this study is to compare the combination of erlotinib and pemetrexed versus either pemetrexed alone and erlotinib alone, in terms of progression-free survival (time until the objective worsening of the disease) in patients who have never smoked and have locally advanced or metastatic Nonsquamous Non-Small Cell Lung Cancer who have failed a first-line chemotherapy treatment."},"conditionsModule":{"conditions":["Non-Small-Cell Lung Cancer"]},"designModule":{"studyType":"INTERVENTIONAL","phases":["PHASE2"],"designInfo":{"allocation":"RANDOMIZED","interventionModel":"PARALLEL","primaryPurpose":"TREATMENT","maskingInfo":{"masking":"NONE"}},"enrollmentInfo":{"count":247,"type":"ACTUAL"}},"armsInterventionsModule":{"armGroups":[{"label":"Pemetrexed + Erlotinib","type":"EXPERIMENTAL","description":"Pemetrexed 500 milligrams per meter squared (mg/m\\^2) of body surface area, administered by intravenous (IV) infusion on Day 1 plus erlotinib 150 mg orally once daily on Day 2 through Day 14 of each 21-day cycle until disease progression or unacceptable toxicity developed or up to 38 months.","interventionNames":["Drug: pemetrexed","Drug: erlotinib"]},{"label":"Erlotinib","type":"ACTIVE_COMPARATOR","description":"Erlotinib 150 mg, administered orally once daily in each 21-day cycle until disease progression or unacceptable toxicity developed or up to 38 months.","interventionNames":["Drug: erlotinib"]},{"label":"Pemetrexed","type":"ACTIVE_COMPARATOR","description":"Pemetrexed 500 mg/m\\^2 of body surface area, administered by IV infusion on Day 1 of each 21-day cycle until progression or unacceptable toxicity developed or up to 38 months.","interventionNames":["Drug: pemetrexed"]}],"interventions":[{"type":"DRUG","name":"pemetrexed","description":"500 milligrams per meter squared (mg/m\\^2), intravenous (IV), every (q) 21 days until progression or unacceptable toxicity develops","armGroupLabels":["Pemetrexed","Pemetrexed + Erlotinib"],"otherNames":["LY231514","Alimta"]},{"type":"DRUG","name":"erlotinib","description":"150 mg, orally, once daily until progression or unacceptable toxicity develops","armGroupLabels":["Erlotinib","Pemetrexed + Erlotinib"]}]},"outcomesModule":{"primaryOutcomes":[{"measure":"Progression-Free Survival (PFS)","description":"PFS is defined as the time from randomization to the first date of progressive disease (PD; either objectively determined or clinical progression) or death from any cause. PD was defined as at least a 20% increase in sum of longest diameter of target lesions as assessed by Response Evaluation Criteria in Solid Tumors (RECIST) version 1.0 guidelines. Time to disease progression was censored at the date of death.","timeFrame":"Randomization to measured PD up to 38 months"}],"secondaryOutcomes":[{"measure":"Percentage of Participants With a Tumor Response of Complete Response (CR) or Partial Response (PR) [Tumor Response Rate (TRR)]","description":"TRR was defined as the number of responders (complete or partial) divided by the number of participants qualified for tumor response, as assessed using the RECIST version 1.0 guideline, multiplied by 100. RECIST guidelines: CR was defined as the disappearance of all target and non-target lesions and any pathological lymph nodes (whether target or non-target) must have reduction in short axis to \\<10 millimeter (mm) and normalization of tumor marker level of non-target lesions; PR was defined as at least a 30% decrease in sum of longest diameter of target lesions.","timeFrame":"Randomization to measured disease progression up to 38 months"},{"measure":"Overall Survival (OS)","description":"OS is defined as the time from randomization to the date of death from any cause.","timeFrame":"Baseline to date of death from any cause up to 45.5 months"},{"measure":"Number of Participants With Adverse Events","description":"A summary of serious and all other non-serious adverse events (AEs), which include AEs reported for pharmacological toxicity, is located in the Reported Adverse Event module.","timeFrame":"Randomization up to 39 months"},{"measure":"Percentage of Participants With CR, PR, and Stable Disease (SD) - Disease Control Rate (DCR)","description":"DCR was defined as the percentage of participants with CR, PR, or SD divided by the number of randomized and treated participants as assessed using the RECIST criteria. CR was defined as the disappearance of all target lesions; PR was defined as 1) at least a 30% decrease in sum of longest diameter of target lesions or 2) complete disappearance of target lesions, with persistence (but not worsening) of 1 or more non-target lesions; PD was defined as at least a 20% increase in sum of longest diameter of target lesions; SD was defined as small changes that did not meet the above criteria.","timeFrame":"Randomization to disease progression up to 38 months"},{"measure":"Time to Worsening of Symptoms (TWS) on Lung Cancer Symptoms Scale (LCSS)","description":"TWS assessed using the LCSS a participant rated lung cancer instrument which consisted of 9 disease related symptoms and quality of life (QoL) items, with 6 subscales related to major lung cancer symptoms (appetite, cough, fatigue, dyspnea, hemoptysis, and pain) and 3 summation items related to QoL (activity status, symptomatic distress, and overall QoL). Each item is marked on a visual analog scale (VAS) 0 (low symptoms/QoL items) to 100 (high symptoms/QoL items). The mean of the 6 subscales is used to calculate the average symptom burden index. TWS was measured from the date of study enrollment to the first date of a worsening in any 1 of the 6 LCSS symptom-specific items (as defined by a VAS 15-mm increase from baseline in the patient-reported score for any of these 6 items).","timeFrame":"Randomization to first date of worsening of any of 6 LCSS symptom specific items or up to 12.4 months"},{"measure":"Number of Participants With Mutated or Non-Mutated Epidermal Growth Factor Receptor (EGFR) Genotype Status","description":"EGFR mutation status was defined as: participants with any mutations detected were categorized as mutated and participants without any mutations detected were categorized as non-mutated.","timeFrame":"Randomization to date of PD or death up to 38 months"},{"measure":"Probability of OS at 12 Months","description":"OS time is censored at the date of last contact for participants who were still alive or lost to follow-up.","timeFrame":"Month 12"}]},"eligibilityModule":{"eligibilityCriteria":"Inclusion Criteria:\n\n* Patients with locally advanced or metastatic nonsquamous non-small cell lung cancer\n* Patients must be non-smokers\n* Patients must have at least one measurable lesion\n* Performance status of 0 to 2 on the Eastern Cooperative Oncology Group Scale\n* Patients must have failed only one prior chemotherapy regimen and must be considered eligible for further chemotherapy following progression of their disease.\n\nExclusion Criteria:\n\n* Patients who have received treatment within the last 30 days with a drug that has not received regulatory approval for any indication\n* Patients who have previously received treatment with drugs against the human epidermal growth factor receptors\n* Patients who have previously received treatment with drugs which have similar targets as Pemetrexed\n* Patients who have any known significant ophthalmologic abnormalities of the surface of the eye\n* Patients who have a history of severe hypersensitivity reaction to erlotinib or pemetrexed","healthyVolunteers":false,"sex":"ALL","minimumAge":"18 Years","stdAges":["ADULT","OLDER_ADULT"]},"contactsLocationsModule":{"overallOfficials":[{"name":"Call 1-877-CTLILLY (1-877-285-4559) or 1-317-615-4559 Mon-Fri 9 AM - 5 PM Eastern time (UTC/GMT - 5 hours, EST)","affiliation":"Eli Lilly and Company","role":"STUDY_DIRECTOR"}],"locations":[{"facility":"For additional information regarding investigative sites for this trial, contact 1-877-CTLILLY (1-877-285-4559, 1-317-615-4559) Mon - Fri from 9 AM to 5 PM Eastern Time (UTC/GMT - 5 hours, EST), or speak with your personal physician.","city":"Barretos","zip":"14784700","country":"Brazil","geoPoint":{"lat":-20.55722,"lon":-48.56778}},{"facility":"For additional information regarding investigative sites for this trial, contact 1-877-CTLILLY (1-877-285-4559, 1-317-615-4559) Mon - Fri from 9 AM to 5 PM Eastern Time (UTC/GMT - 5 hours, EST), or speak with your personal physician.","city":"Ijuí","zip":"98700 000","country":"Brazil","geoPoint":{"lat":-28.38778,"lon":-53.91472}},{"facility":"For additional information regarding investigative sites for this trial, contact 1-877-CTLILLY (1-877-285-4559, 1-317-615-4559) Mon - Fri from 9 AM to 5 PM Eastern Time (UTC/GMT - 5 hours, EST), or speak with your personal physician.","city":"São Paulo","zip":"01277-900","country":"Brazil","geoPoint":{"lat":-23.5475,"lon":-46.63611}},{"facility":"For additional information regarding investigative sites for this trial, contact 1-877-CTLILLY (1-877-285-4559, 1-317-615-4559) Mon - Fri from 9 AM to 5 PM Eastern Time (UTC/GMT - 5 hours, EST), or speak with your personal physician.","city":"Beijing","zip":"100730","country":"China","geoPoint":{"lat":39.9075,"lon":116.39723}},{"facility":"For additional information regarding investigative sites for this trial, contact 1-877-CTLILLY (1-877-285-4559, 1-317-615-4559) Mon - Fri from 9 AM to 5 PM Eastern Time (UTC/GMT - 5 hours, EST), or speak with your personal physician.","city":"Nanning","zip":"530000","country":"China","geoPoint":{"lat":22.81667,"lon":108.31667}},{"facility":"For additional information regarding investigative sites for this trial, contact 1-877-CTLILLY (1-877-285-4559, 1-317-615-4559) Mon - Fri from 9 AM to 5 PM Eastern Time (UTC/GMT - 5 hours, EST), or speak with your personal physician.","city":"Shanghai","zip":"200030","country":"China","geoPoint":{"lat":31.22222,"lon":121.45806}},{"facility":"For additional information regarding investigative sites for this trial, contact 1-877-CTLILLY (1-877-285-4559, 1-317-615-4559) Mon - Fri from 9 AM to 5 PM Eastern Time (UTC/GMT - 5 hours, EST), or speak with your personal physician.","city":"Shatin","country":"Hong Kong","geoPoint":{"lat":22.38333,"lon":114.18333}},{"facility":"For additional information regarding investigative sites for this trial, contact 1-877-CTLILLY (1-877-285-4559, 1-317-615-4559) Mon - Fri from 9 AM to 5 PM Eastern Time (UTC/GMT - 5 hours, EST), or speak with your personal physician.","city":"Ahmedabad","zip":"380016","country":"India","geoPoint":{"lat":23.02579,"lon":72.58727}},{"facility":"For additional information regarding investigative sites for this trial, contact 1-877-CTLILLY (1-877-285-4559, 1-317-615-4559) Mon - Fri from 9 AM to 5 PM Eastern Time (UTC/GMT - 5 hours, EST), or speak with your personal physician.","city":"Bhopal","zip":"462001","country":"India","geoPoint":{"lat":23.25469,"lon":77.40289}},{"facility":"For additional information regarding investigative sites for this trial, contact 1-877-CTLILLY (1-877-285-4559, 1-317-615-4559) Mon - Fri from 9 AM to 5 PM Eastern Time (UTC/GMT - 5 hours, EST), or speak with your personal physician.","city":"Hyderabaad","zip":"500082","country":"India"},{"facility":"For additional information regarding investigative sites for this trial, contact 1-877-CTLILLY (1-877-285-4559, 1-317-615-4559) Mon - Fri from 9 AM to 5 PM Eastern Time (UTC/GMT - 5 hours, EST), or speak with your personal physician.","city":"Jaipur","zip":"302013","country":"India","geoPoint":{"lat":26.91962,"lon":75.78781}},{"facility":"For additional information regarding investigative sites for this trial, contact 1-877-CTLILLY (1-877-285-4559, 1-317-615-4559) Mon - Fri from 9 AM to 5 PM Eastern Time (UTC/GMT - 5 hours, EST), or speak with your personal physician.","city":"Kochi","zip":"682304","country":"India","geoPoint":{"lat":9.93988,"lon":76.26022}},{"facility":"For additional information regarding investigative sites for this trial, contact 1-877-CTLILLY (1-877-285-4559, 1-317-615-4559) Mon - Fri from 9 AM to 5 PM Eastern Time (UTC/GMT - 5 hours, EST), or speak with your personal physician.","city":"Kolkata","zip":"700 026","country":"India","geoPoint":{"lat":22.56263,"lon":88.36304}},{"facility":"For additional information regarding investigative sites for this trial, contact 1-877-CTLILLY (1-877-285-4559, 1-317-615-4559) Mon - Fri from 9 AM to 5 PM Eastern Time (UTC/GMT - 5 hours, EST), or speak with your personal physician.","city":"Madurai","zip":"625020","country":"India","geoPoint":{"lat":9.919,"lon":78.11953}},{"facility":"For additional information regarding investigative sites for this trial, contact 1-877-CTLILLY (1-877-285-4559, 1-317-615-4559) Mon - Fri from 9 AM to 5 PM Eastern Time (UTC/GMT - 5 hours, EST), or speak with your personal physician.","city":"Mohali","zip":"160062","country":"India","geoPoint":{"lat":30.67995,"lon":76.72211}},{"facility":"For additional information regarding investigative sites for this trial, contact 1-877-CTLILLY (1-877-285-4559, 1-317-615-4559) Mon - Fri from 9 AM to 5 PM Eastern Time (UTC/GMT - 5 hours, EST), or speak with your personal physician.","city":"Mumbai","zip":"400 026","country":"India","geoPoint":{"lat":19.07283,"lon":72.88261}},{"facility":"For additional information regarding investigative sites for this trial, contact 1-877-CTLILLY (1-877-285-4559, 1-317-615-4559) Mon - Fri from 9 AM to 5 PM Eastern Time (UTC/GMT - 5 hours, EST), or speak with your personal physician.","city":"New Delhi","zip":"110017","country":"India","geoPoint":{"lat":28.62137,"lon":77.2148}},{"facility":"For additional information regarding investigative sites for this trial, contact 1-877-CTLILLY (1-877-285-4559, 1-317-615-4559) Mon - Fri from 9 AM to 5 PM Eastern Time (UTC/GMT - 5 hours, EST), or speak with your personal physician.","city":"Visakhapatnam","zip":"530002","country":"India","geoPoint":{"lat":17.68009,"lon":83.20161}},{"facility":"For additional information regarding investigative sites for this trial, contact 1-877-CTLILLY (1-877-285-4559, 1-317-615-4559) Mon - Fri from 9 AM to 5 PM Eastern Time (UTC/GMT - 5 hours, EST), or speak with your personal physician.","city":"Jinju","zip":"660-702","country":"South Korea","geoPoint":{"lat":35.19278,"lon":128.08472}},{"facility":"For additional information regarding investigative sites for this trial, contact 1-877-CTLILLY (1-877-285-4559, 1-317-615-4559) Mon - Fri from 9 AM to 5 PM Eastern Time (UTC/GMT - 5 hours, EST), or speak with your personal physician.","city":"Seoul","zip":"138-736","country":"South Korea","geoPoint":{"lat":37.566,"lon":126.9784}},{"facility":"For additional information regarding investigative sites for this trial, contact 1-877-CTLILLY (1-877-285-4559, 1-317-615-4559) Mon - Fri from 9 AM to 5 PM Eastern Time (UTC/GMT - 5 hours, EST), or speak with your personal physician.","city":"Suwon","zip":"442-723","country":"South Korea","geoPoint":{"lat":37.29111,"lon":127.00889}},{"facility":"For additional information regarding investigative sites for this trial, contact 1-877-CTLILLY (1-877-285-4559, 1-317-615-4559) Mon - Fri from 9 AM to 5 PM Eastern Time (UTC/GMT - 5 hours, EST), or speak with your personal physician.","city":"Changhua","zip":"500","country":"Taiwan","geoPoint":{"lat":24.0692,"lon":120.5512}},{"facility":"For additional information regarding investigative sites for this trial, contact 1-877-CTLILLY (1-877-285-4559, 1-317-615-4559) Mon - Fri from 9 AM to 5 PM Eastern Time (UTC/GMT - 5 hours, EST), or speak with your personal physician.","city":"Taichung","zip":"407","country":"Taiwan","geoPoint":{"lat":24.1469,"lon":120.6839}},{"facility":"For additional information regarding investigative sites for this trial, contact 1-877-CTLILLY (1-877-285-4559, 1-317-615-4559) Mon - Fri from 9 AM to 5 PM Eastern Time (UTC/GMT - 5 hours, EST), or speak with your personal physician.","city":"Taoyuan District","zip":"333","country":"Taiwan","geoPoint":{"lat":24.9896,"lon":121.3187}},{"facility":"For additional information regarding investigative sites for this trial, contact 1-877-CTLILLY (1-877-285-4559, 1-317-615-4559) Mon - Fri from 9 AM to 5 PM Eastern Time (UTC/GMT - 5 hours, EST), or speak with your personal physician.","city":"Poole","state":"Dorset","zip":"BH15 2JB","country":"United Kingdom","geoPoint":{"lat":50.71429,"lon":-1.98458}},{"facility":"For additional information regarding investigative sites for this trial, contact 1-877-CTLILLY (1-877-285-4559, 1-317-615-4559) Mon - Fri from 9 AM to 5 PM Eastern Time (UTC/GMT - 5 hours, EST), or speak with your personal physician.","city":"Chelmsford","state":"Essex","zip":"CM1 7ET","country":"United Kingdom","geoPoint":{"lat":51.73575,"lon":0.46958}},{"facility":"For additional information regarding investigative sites for this trial, contact 1-877-CTLILLY (1-877-285-4559, 1-317-615-4559) Mon - Fri from 9 AM to 5 PM Eastern Time (UTC/GMT - 5 hours, EST), or speak with your personal physician.","city":"Aberdeen","state":"Scotland","zip":"AB25 2ZN","country":"United Kingdom","geoPoint":{"lat":57.14369,"lon":-2.09814}},{"facility":"For additional information regarding investigative sites for this trial, contact 1-877-CTLILLY (1-877-285-4559, 1-317-615-4559) Mon - Fri from 9 AM to 5 PM Eastern Time (UTC/GMT - 5 hours, EST), or speak with your personal physician.","city":"Guildford","state":"Surrey","zip":"GU2 7XX","country":"United Kingdom","geoPoint":{"lat":51.23536,"lon":-0.57427}},{"facility":"For additional information regarding investigative sites for this trial, contact 1-877-CTLILLY (1-877-285-4559, 1-317-615-4559) Mon - Fri from 9 AM to 5 PM Eastern Time (UTC/GMT - 5 hours, EST), or speak with your personal physician.","city":"Manchester","state":"United Kingdom","zip":"M20 4BX","country":"United Kingdom","geoPoint":{"lat":53.48095,"lon":-2.23743}}]},"referencesModule":{"references":[{"pmid":"23890768","type":"DERIVED","citation":"Lee DH, Lee JS, Kim SW, Rodrigues-Pereira J, Han B, Song XQ, Wang J, Kim HK, Sahoo TP, Digumarti R, Wang X, Altug S, Orlando M. Three-arm randomised controlled phase 2 study comparing pemetrexed and erlotinib to either pemetrexed or erlotinib alone as second-line treatment for never-smokers with non-squamous non-small cell lung cancer. Eur J Cancer. 2013 Oct;49(15):3111-21. doi: 10.1016/j.ejca.2013.06.035. Epub 2013 Jul 24."}],"seeAlsoLinks":[{"label":"Lilly Clinical Trial Registry","url":"http://www.lillytrials.com"}]}},"resultsSection":{"participantFlowModule":{"groups":[{"id":"FG000","title":"Pemetrexed + Erlotinib","description":"Pemetrexed 500 milligrams per meter squared (mg/m\\^2) of body surface area, administered by intravenous (IV) infusion on Day 1 plus erlotinib 150 mg orally once daily on Day 2 through Day 14 of each 21-day cycle until disease progression or unacceptable toxicity developed or up to 38 months."},{"id":"FG001","title":"Erlotinib","description":"Erlotinib 150 mg, administered orally once daily in each 21-day cycle until disease progression or unacceptable toxicity developed or up to 38 months."},{"id":"FG002","title":"Pemetrexed","description":"Pemetrexed 500 mg/m\\^2 of body surface area, administered by IV infusion on Day 1 of each 21-day cycle until progression or unacceptable toxicity developed or up to 38 months."}],"periods":[{"title":"Overall Study","milestones":[{"type":"STARTED","achievements":[{"groupId":"FG000","numSubjects":"81"},{"groupId":"FG001","numSubjects":"82"},{"groupId":"FG002","numSubjects":"84"}]},{"type":"Qualified Participants","achievements":[{"groupId":"FG000","comment":"Participants with tumors of nonsquamous histology","numSubjects":"78"},{"groupId":"FG001","comment":"Participants with tumors of nonsquamous histology","numSubjects":"82"},{"groupId":"FG002","comment":"Participants with tumors of nonsquamous histology","numSubjects":"80"}]},{"type":"Not Discontinued at 18 Months","achievements":[{"groupId":"FG000","numSubjects":"9"},{"groupId":"FG001","numSubjects":"19"},{"groupId":"FG002","numSubjects":"11"}]},{"type":"COMPLETED","achievements":[{"groupId":"FG000","numSubjects":"9"},{"groupId":"FG001","numSubjects":"19"},{"groupId":"FG002","numSubjects":"11"}]},{"type":"NOT COMPLETED","achievements":[{"groupId":"FG000","numSubjects":"72"},{"groupId":"FG001","numSubjects":"63"},{"groupId":"FG002","numSubjects":"73"}]}],"dropWithdraws":[{"type":"Death","reasons":[{"groupId":"FG000","numSubjects":"45"},{"groupId":"FG001","numSubjects":"38"},{"groupId":"FG002","numSubjects":"50"}]},{"type":"Physician Decision","reasons":[{"groupId":"FG000","numSubjects":"1"},{"groupId":"FG001","numSubjects":"2"},{"groupId":"FG002","numSubjects":"2"}]},{"type":"Withdrawal by Subject","reasons":[{"groupId":"FG000","numSubjects":"9"},{"groupId":"FG001","numSubjects":"12"},{"groupId":"FG002","numSubjects":"17"}]},{"type":"Sponsor Decision","reasons":[{"groupId":"FG000","numSubjects":"13"},{"groupId":"FG001","numSubjects":"7"},{"groupId":"FG002","numSubjects":"1"}]},{"type":"Lost to Follow-up","reasons":[{"groupId":"FG000","numSubjects":"4"},{"groupId":"FG001","numSubjects":"4"},{"groupId":"FG002","numSubjects":"3"}]}]}]},"baselineCharacteristicsModule":{"groups":[{"id":"BG000","title":"Pemetrexed + Erlotinib","description":"Pemetrexed 500 mg/m\\^2 of body surface area, administered by IV infusion on Day 1 plus erlotinib 150 mg orally once daily on Day 2 through Day 14 of each 21-day cycle until disease progression or unacceptable toxicity developed or up to 38 months."},{"id":"BG001","title":"Erlotinib","description":"Erlotinib 150 mg, administered orally once daily in each 21-day cycle until disease progression or unacceptable toxicity developed or up to 38 months."},{"id":"BG002","title":"Pemetrexed","description":"Pemetrexed 500 mg/m\\^2 of body surface area, administered by IV infusion on Day 1 of each 21-day cycle until progression or unacceptable toxicity developed or up to 38 months."},{"id":"BG003","title":"Total","description":"Total of all reporting groups"}],"denoms":[{"units":"Participants","counts":[{"groupId":"BG000","value":"78"},{"groupId":"BG001","value":"82"},{"groupId":"BG002","value":"80"},{"groupId":"BG003","value":"240"}]}],"measures":[{"title":"Age Continuous","paramType":"MEAN","dispersionType":"STANDARD_DEVIATION","unitOfMeasure":"years","classes":[{"categories":[{"measurements":[{"groupId":"BG000","value":"56.0","spread":"11.72"},{"groupId":"BG001","value":"53.9","spread":"10.49"},{"groupId":"BG002","value":"56.1","spread":"13.04"},{"groupId":"BG003","value":"55.3","spread":"11.78"}]}]}]},{"title":"Sex: Female, Male","paramType":"COUNT_OF_PARTICIPANTS","unitOfMeasure":"Participants","classes":[{"categories":[{"title":"Female","measurements":[{"groupId":"BG000","value":"58"},{"groupId":"BG001","value":"54"},{"groupId":"BG002","value":"45"},{"groupId":"BG003","value":"157"}]},{"title":"Male","measurements":[{"groupId":"BG000","value":"20"},{"groupId":"BG001","value":"28"},{"groupId":"BG002","value":"35"},{"groupId":"BG003","value":"83"}]}]}]},{"title":"Race/Ethnicity, Customized","paramType":"NUMBER","unitOfMeasure":"participants","classes":[{"title":"Caucasian","categories":[{"measurements":[{"groupId":"BG000","value":"18"},{"groupId":"BG001","value":"6"},{"groupId":"BG002","value":"11"},{"groupId":"BG003","value":"35"}]}]},{"title":"African","categories":[{"measurements":[{"groupId":"BG000","value":"2"},{"groupId":"BG001","value":"0"},{"groupId":"BG002","value":"1"},{"groupId":"BG003","value":"3"}]}]},{"title":"East Asian (enrolled in an East Asian country)","categories":[{"measurements":[{"groupId":"BG000","value":"41"},{"groupId":"BG001","value":"49"},{"groupId":"BG002","value":"43"},{"groupId":"BG003","value":"133"}]}]},{"title":"East Asian (enrolled in non-East Asian Country)","categories":[{"measurements":[{"groupId":"BG000","value":"4"},{"groupId":"BG001","value":"2"},{"groupId":"BG002","value":"1"},{"groupId":"BG003","value":"7"}]}]},{"title":"West Asian","categories":[{"measurements":[{"groupId":"BG000","value":"13"},{"groupId":"BG001","value":"25"},{"groupId":"BG002","value":"24"},{"groupId":"BG003","value":"62"}]}]}]},{"title":"Region of Enrollment","paramType":"NUMBER","unitOfMeasure":"participants","classes":[{"title":"Australia","categories":[{"measurements":[{"groupId":"BG000","value":"3"},{"groupId":"BG001","value":"0"},{"groupId":"BG002","value":"0"},{"groupId":"BG003","value":"3"}]}]},{"title":"Brazil","categories":[{"measurements":[{"groupId":"BG000","value":"15"},{"groupId":"BG001","value":"5"},{"groupId":"BG002","value":"8"},{"groupId":"BG003","value":"28"}]}]},{"title":"China","categories":[{"measurements":[{"groupId":"BG000","value":"14"},{"groupId":"BG001","value":"17"},{"groupId":"BG002","value":"15"},{"groupId":"BG003","value":"46"}]}]},{"title":"Hong Kong","categories":[{"measurements":[{"groupId":"BG000","value":"0"},{"groupId":"BG001","value":"3"},{"groupId":"BG002","value":"2"},{"groupId":"BG003","value":"5"}]}]},{"title":"India","categories":[{"measurements":[{"groupId":"BG000","value":"15"},{"groupId":"BG001","value":"27"},{"groupId":"BG002","value":"25"},{"groupId":"BG003","value":"67"}]}]},{"title":"Korea, Republic of","categories":[{"measurements":[{"groupId":"BG000","value":"20"},{"groupId":"BG001","value":"20"},{"groupId":"BG002","value":"13"},{"groupId":"BG003","value":"53"}]}]},{"title":"Taiwan","categories":[{"measurements":[{"groupId":"BG000","value":"7"},{"groupId":"BG001","value":"9"},{"groupId":"BG002","value":"13"},{"groupId":"BG003","value":"29"}]}]},{"title":"United Kingdom","categories":[{"measurements":[{"groupId":"BG000","value":"4"},{"groupId":"BG001","value":"1"},{"groupId":"BG002","value":"4"},{"groupId":"BG003","value":"9"}]}]}]},{"title":"Height at Baseline","paramType":"MEAN","dispersionType":"STANDARD_DEVIATION","unitOfMeasure":"centimeter (cm)","classes":[{"categories":[{"measurements":[{"groupId":"BG000","value":"159.3","spread":"8.70"},{"groupId":"BG001","value":"160.3","spread":"8.38"},{"groupId":"BG002","value":"160.1","spread":"8.84"},{"groupId":"BG003","value":"159.9","spread":"8.61"}]}]}]},{"title":"Weight at Baseline","paramType":"MEAN","dispersionType":"STANDARD_DEVIATION","unitOfMeasure":"kilogram (kg)","classes":[{"categories":[{"measurements":[{"groupId":"BG000","value":"59.6","spread":"11.76"},{"groupId":"BG001","value":"59.9","spread":"12.17"},{"groupId":"BG002","value":"58.9","spread":"10.82"},{"groupId":"BG003","value":"59.5","spread":"11.56"}]}]}]},{"title":"Body Mass Index (BMI)","description":"BMI is an estimate of body fat based on body weight divided by height squared.","paramType":"MEAN","dispersionType":"STANDARD_DEVIATION","unitOfMeasure":"kilogram per meter squared (kg/m^2)","classes":[{"categories":[{"measurements":[{"groupId":"BG000","value":"23.5","spread":"4.54"},{"groupId":"BG001","value":"23.3","spread":"3.87"},{"groupId":"BG002","value":"23.0","spread":"3.87"},{"groupId":"BG003","value":"23.2","spread":"4.09"}]}]}]},{"title":"Body Surface Area (BSA)","paramType":"MEAN","dispersionType":"STANDARD_DEVIATION","unitOfMeasure":"meter squared (m^2)","classes":[{"categories":[{"measurements":[{"groupId":"BG000","value":"1.6","spread":"0.17"},{"groupId":"BG001","value":"1.6","spread":"0.18"},{"groupId":"BG002","value":"1.6","spread":"0.17"},{"groupId":"BG003","value":"1.6","spread":"0.17"}]}]}]},{"title":"Eastern Cooperative Oncology Group Performance Status (ECOG PS)","description":"ECOG PS Scale: 0 = fully active, able to perform all pre-disease activities unrestricted; 1 = restricted in physically strenuous activity but ambulatory, able to carry out light or sedentary activities; 2 = ambulatory, capable of all self-care but unable to carry out any work activities, up and about more than 50% of waking hours; 3 = capable of only limited self-care, confined to bed or chair more than 50% of waking hours; 4 = completely disabled, cannot carry on any self-care, totally confined to bed or chair; 5 = Dead.","paramType":"NUMBER","unitOfMeasure":"participant","classes":[{"title":"0","categories":[{"measurements":[{"groupId":"BG000","value":"10"},{"groupId":"BG001","value":"20"},{"groupId":"BG002","value":"16"},{"groupId":"BG003","value":"46"}]}]},{"title":"1","categories":[{"measurements":[{"groupId":"BG000","value":"61"},{"groupId":"BG001","value":"56"},{"groupId":"BG002","value":"60"},{"groupId":"BG003","value":"177"}]}]},{"title":"2","categories":[{"measurements":[{"groupId":"BG000","value":"6"},{"groupId":"BG001","value":"6"},{"groupId":"BG002","value":"4"},{"groupId":"BG003","value":"16"}]}]},{"title":"3","categories":[{"measurements":[{"groupId":"BG000","value":"1"},{"groupId":"BG001","value":"0"},{"groupId":"BG002","value":"0"},{"groupId":"BG003","value":"1"}]}]}]},{"title":"Histological Subtype","paramType":"NUMBER","unitOfMeasure":"participants","classes":[{"title":"Adenocarcinoma (adeno)","categories":[{"measurements":[{"groupId":"BG000","value":"72"},{"groupId":"BG001","value":"76"},{"groupId":"BG002","value":"77"},{"groupId":"BG003","value":"225"}]}]},{"title":"Non-adenocarcinoma (non-adeno)","categories":[{"measurements":[{"groupId":"BG000","value":"6"},{"groupId":"BG001","value":"6"},{"groupId":"BG002","value":"3"},{"groupId":"BG003","value":"15"}]}]}]}]},"outcomeMeasuresModule":{"outcomeMeasures":[{"type":"PRIMARY","title":"Progression-Free Survival (PFS)","description":"PFS is defined as the time from randomization to the first date of progressive disease (PD; either objectively determined or clinical progression) or death from any cause. PD was defined as at least a 20% increase in sum of longest diameter of target lesions as assessed by Response Evaluation Criteria in Solid Tumors (RECIST) version 1.0 guidelines. Time to disease progression was censored at the date of death.","populationDescription":"Qualified Intent to Treat (Q-ITT) Population defined as all participants with nonsquamous histology, who were randomized to therapy.","reportingStatus":"POSTED","paramType":"MEDIAN","dispersionType":"95% Confidence Interval","unitOfMeasure":"months","timeFrame":"Randomization to measured PD up to 38 months","groups":[{"id":"OG000","title":"Pemetrexed + Erlotinib","description":"Pemetrexed 500 mg/m\\^2 of BSA, administered by IV infusion on Day 1 plus erlotinib 150 mg orally once daily on Day 2 through Day 14 of each 21-day cycle until disease progression or unacceptable toxicity developed or up to 38 months."},{"id":"OG001","title":"Erlotinib","description":"Erlotinib 150 mg, administered orally once daily in each 21-day cycle until disease progression or unacceptable toxicity developed or up to 38 months."},{"id":"OG002","title":"Pemetrexed","description":"Pemetrexed 500 mg/m\\^2 of BSA, administered by IV infusion on Day 1 of each 21-day cycle until progression or unacceptable toxicity developed or up to 38 months."}],"denoms":[{"units":"Participants","counts":[{"groupId":"OG000","value":"78"},{"groupId":"OG001","value":"82"},{"groupId":"OG002","value":"80"}]}],"classes":[{"categories":[{"measurements":[{"groupId":"OG000","value":"7.4","lowerLimit":"4.4","upperLimit":"12.9"},{"groupId":"OG001","value":"3.8","lowerLimit":"2.7","upperLimit":"6.3"},{"groupId":"OG002","value":"4.4","lowerLimit":"3.0","upperLimit":"6.0"}]}]}],"analyses":[{"groupIds":["OG000","OG001","OG002"],"groupDescription":"Overall; Global null hypothesis was rejected at 2-sided 0.2 significance level.","testedNonInferiority":false,"nonInferiorityType":"SUPERIORITY_OR_OTHER","pValue":"0.003","pValueComment":"If global test across 3 arms is significant at a 2-sided 0.2 level, then conduct 2-sided pairwise tests between combination and each single agent under the global model. Significance is claimed only if both the global and pairwise tests p\\<0.05.","statisticalMethod":"Regression, Cox","statisticalComment":"Model is adjusted to covariates ECOG PS (0/1 vs.2), histological subtype (adeno vs. non-adeno), race (East Asian and non-East Asian) and gender."},{"groupIds":["OG000","OG001"],"groupDescription":"Primary Analysis; Global null hypothesis was rejected at 2-sided 0.2 significance level.","testedNonInferiority":false,"nonInferiorityType":"SUPERIORITY_OR_OTHER","pValue":"0.002","pValueComment":"If global test across 3 arms is significant at a 2-sided 0.2 level, then conduct 2-sided pairwise tests between combination and each single agent under the global model. Significance is claimed only if both the global and pairwise tests p\\<0.05.","statisticalMethod":"Regression, Cox","statisticalComment":"Model is adjusted to covariates ECOG PS (0/1 vs.2), histological subtype (adeno vs. non-adeno), race (East Asian and non-East Asian) and gender.","paramType":"Hazard Ratio (HR)","paramValue":"0.57","ciPctValue":"95","ciNumSides":"TWO_SIDED","ciLowerLimit":"0.40","ciUpperLimit":"0.81"},{"groupIds":["OG000","OG002"],"groupDescription":"Primary Analysis; Global null hypothesis was rejected at 2-sided 0.2 significance level.","testedNonInferiority":false,"nonInferiorityType":"SUPERIORITY_OR_OTHER","pValue":"0.005","pValueComment":"If global test across 3 arms is significant at a 2-sided 0.2 level, then conduct 2-sided pairwise tests between combination and each single agent under the global model. Significance is claimed only if both the global and pairwise tests p\\<0.05.","statisticalMethod":"Regression, Cox","statisticalComment":"Model is adjusted to covariates ECOG PS (0/1 vs.2), histological subtype (adeno vs. non-adeno), race (East Asian and non-East Asian) and gender.","paramType":"Hazard Ratio (HR)","paramValue":"0.58","ciPctValue":"95","ciNumSides":"TWO_SIDED","ciLowerLimit":"0.39","ciUpperLimit":"0.85"},{"groupIds":["OG001","OG002"],"groupDescription":"Secondary Analysis; Global null hypothesis was rejected at 2-sided 0.2 significance level.","testedNonInferiority":false,"nonInferiorityType":"SUPERIORITY_OR_OTHER","pValue":"0.959","pValueComment":"If global test across 3 arms is significant at a 2-sided 0.2 level, then conduct 2-sided pairwise tests between combination and each single agent under the global model. Significance is claimed only if both the global and pairwise tests p\\<0.05.","statisticalMethod":"Regression, Cox","statisticalComment":"Model is adjusted to covariates ECOG PS (0/1 vs.2), histological subtype (adeno vs. non-adeno), race (East Asian and non-East Asian) and gender.","paramType":"Hazard Ratio, log","paramValue":"0.99","ciPctValue":"95","ciNumSides":"TWO_SIDED","ciLowerLimit":"0.70","ciUpperLimit":"1.40"}]},{"type":"SECONDARY","title":"Percentage of Participants With a Tumor Response of Complete Response (CR) or Partial Response (PR) [Tumor Response Rate (TRR)]","description":"TRR was defined as the number of responders (complete or partial) divided by the number of participants qualified for tumor response, as assessed using the RECIST version 1.0 guideline, multiplied by 100. RECIST guidelines: CR was defined as the disappearance of all target and non-target lesions and any pathological lymph nodes (whether target or non-target) must have reduction in short axis to \\<10 millimeter (mm) and normalization of tumor marker level of non-target lesions; PR was defined as at least a 30% decrease in sum of longest diameter of target lesions.","populationDescription":"Q-ITT Population - Tumor Analyzable (Q-ITT-TA) Population: defined as all participants with nonsquamous histology, who were randomized to therapy and had measurable or evaluable lesions at baseline.","reportingStatus":"POSTED","paramType":"NUMBER","unitOfMeasure":"percentage of participants","timeFrame":"Randomization to measured disease progression up to 38 months","groups":[{"id":"OG000","title":"Pemetrexed + Erlotinib","description":"Pemetrexed 500 mg/m\\^2 of BSA, administered by IV infusion on Day 1 plus erlotinib 150 mg orally once daily on Day 2 through Day 14 of each 21-day cycle until disease progression or unacceptable toxicity developed or up to 38 months."},{"id":"OG001","title":"Erlotinib","description":"Erlotinib 150 mg, administered orally once daily in each 21-day cycle until disease progression or unacceptable toxicity developed or up to 38 months."},{"id":"OG002","title":"Pemetrexed","description":"Pemetrexed 500 mg/m\\^2 of BSA, administered by IV infusion on Day 1 of each 21-day cycle until progression or unacceptable toxicity developed or up to 38 months."}],"denoms":[{"units":"Participants","counts":[{"groupId":"OG000","value":"76"},{"groupId":"OG001","value":"82"},{"groupId":"OG002","value":"80"}]}],"classes":[{"categories":[{"measurements":[{"groupId":"OG000","value":"44.7"},{"groupId":"OG001","value":"29.3"},{"groupId":"OG002","value":"10.0"}]}]}],"analyses":[{"groupIds":["OG000","OG001","OG002"],"testedNonInferiority":false,"nonInferiorityType":"SUPERIORITY_OR_OTHER","pValue":"<0.001","statisticalMethod":"Regression, Logistic","statisticalComment":"Model is adjusted to covariates ECOG PS (0/1 vs.2), histological subtype (adeno vs. non-adeno), race (East Asian and non-East Asian) and gender."},{"groupIds":["OG000","OG001"],"testedNonInferiority":false,"nonInferiorityType":"SUPERIORITY_OR_OTHER","pValue":"0.031","statisticalMethod":"Regression, Logistic","statisticalComment":"Model is adjusted to covariates ECOG PS (0/1 vs.2), histological subtype (adeno vs. non-adeno), race (East Asian and non-East Asian) and gender.","paramType":"Odds Ratio (OR)","paramValue":"2.09","ciPctValue":"95","ciNumSides":"TWO_SIDED","ciLowerLimit":"1.07","ciUpperLimit":"4.09"},{"groupIds":["OG000","OG002"],"testedNonInferiority":false,"nonInferiorityType":"SUPERIORITY_OR_OTHER","pValue":"<0.001","statisticalMethod":"Regression, Logistic","statisticalComment":"Model is adjusted to covariates ECOG PS (0/1 vs.2), histological subtype (adeno vs. non-adeno), race (East Asian and non-East Asian) and gender.","paramType":"Odds Ratio (OR)","paramValue":"7.68","ciPctValue":"95","ciNumSides":"TWO_SIDED","ciLowerLimit":"3.19","ciUpperLimit":"18.48"},{"groupIds":["OG001","OG002"],"testedNonInferiority":false,"nonInferiorityType":"SUPERIORITY_OR_OTHER","pValue":"0.004","statisticalMethod":"Regression, Logistic","statisticalComment":"Model is adjusted to covariates ECOG PS (0/1 vs.2), histological subtype (adeno vs. non-adeno), race (East Asian and non-East Asian) and gender.","paramType":"Odds Ratio, log","paramValue":"0.27","ciPctValue":"95","ciNumSides":"TWO_SIDED","ciLowerLimit":"0.11","ciUpperLimit":"0.66"}]},{"type":"SECONDARY","title":"Overall Survival (OS)","description":"OS is defined as the time from randomization to the date of death from any cause.","populationDescription":"Q-ITT Population: defined as all participants with nonsquamous histology, who were randomized to therapy. Survival time was censored at the date of last contact for participants who were still alive or lost to follow-up, number of participants censored 35 (pemetrexed plus erlotinib), 44 (erlotinib) and 31 (pemetrexed).","reportingStatus":"POSTED","paramType":"MEDIAN","dispersionType":"95% Confidence Interval","unitOfMeasure":"months","timeFrame":"Baseline to date of death from any cause up to 45.5 months","groups":[{"id":"OG000","title":"Pemetrexed + Erlotinib","description":"Pemetrexed 500 mg/m\\^2 of BSA, administered by IV infusion on Day 1 plus erlotinib 150 mg orally once daily on Day 2 through Day 14 of each 21-day cycle until disease progression or unacceptable toxicity developed or up to 38 months."},{"id":"OG001","title":"Erlotinib","description":"Erlotinib 150 mg, administered orally once daily in each 21-day cycle until disease progression or unacceptable toxicity developed or up to 38 months."},{"id":"OG002","title":"Pemetrexed","description":"Pemetrexed 500 mg/m\\^2 of BSA, administered by IV infusion on Day 1 of each 21-day cycle until progression or unacceptable toxicity developed or up to 38 months."}],"denoms":[{"units":"Participants","counts":[{"groupId":"OG000","value":"78"},{"groupId":"OG001","value":"82"},{"groupId":"OG002","value":"80"}]}],"classes":[{"categories":[{"measurements":[{"groupId":"OG000","value":"20.5","lowerLimit":"17.1","upperLimit":"25.0"},{"groupId":"OG001","value":"22.8","lowerLimit":"18.2","upperLimit":"29.5"},{"groupId":"OG002","value":"17.7","lowerLimit":"11.8","upperLimit":"25.3"}]}]}],"analyses":[{"groupIds":["OG000","OG001","OG002"],"testedNonInferiority":false,"nonInferiorityType":"SUPERIORITY_OR_OTHER","pValue":"0.194","statisticalMethod":"Regression, Cox","statisticalComment":"Model is adjusted to covariates ECOG PS (0/1 vs.2), histological subtype (adeno vs. non-adeno), race (East Asian and non-East Asian) and gender."},{"groupIds":["OG000","OG001"],"testedNonInferiority":false,"nonInferiorityType":"SUPERIORITY_OR_OTHER","pValue":"0.747","statisticalMethod":"Regression, Cox","statisticalComment":"Model is adjusted to covariates ECOG PS (0/1 vs.2), histological subtype (adeno vs. non-adeno), race (East Asian and non-East Asian) and gender.","paramType":"Hazard Ratio (HR)","paramValue":"1.08","ciPctValue":"95","ciNumSides":"TWO_SIDED","ciLowerLimit":"0.69","ciUpperLimit":"1.67"},{"groupIds":["OG000","OG002"],"testedNonInferiority":false,"nonInferiorityType":"SUPERIORITY_OR_OTHER","pValue":"0.168","statisticalMethod":"Regression, Cox","statisticalComment":"Model is adjusted to covariates ECOG PS (0/1 vs.2), histological subtype (adeno vs. non-adeno), race (East Asian and non-East Asian) and gender.","paramType":"Hazard Ratio (HR)","paramValue":"0.75","ciPctValue":"95","ciNumSides":"TWO_SIDED","ciLowerLimit":"0.49","ciUpperLimit":"1.13"},{"groupIds":["OG001","OG002"],"testedNonInferiority":false,"nonInferiorityType":"SUPERIORITY_OR_OTHER","pValue":"0.094","statisticalMethod":"Regression, Cox","statisticalComment":"Model is adjusted to covariates ECOG PS (0/1 vs.2), histological subtype (adeno vs. non-adeno), race (East Asian and non-East Asian) and gender.","paramType":"Hazard Ratio (HR)","paramValue":"1.44","ciPctValue":"95","ciNumSides":"TWO_SIDED","ciLowerLimit":"0.94","ciUpperLimit":"2.21"}]},{"type":"SECONDARY","title":"Number of Participants With Adverse Events","description":"A summary of serious and all other non-serious adverse events (AEs), which include AEs reported for pharmacological toxicity, is located in the Reported Adverse Event module.","populationDescription":"Safety Population defined as non-squamous participants who received at least 1 dose of study therapy (pemetrexed plus erlotinib or pemetrexed or erlotinib). One participant was assigned to pemetrexed (single therapy) but received erlotinib (single therapy) at first cycle and this lead to the discrepancy of participants for the safety analysis.","reportingStatus":"POSTED","paramType":"NUMBER","unitOfMeasure":"participants","timeFrame":"Randomization up to 39 months","groups":[{"id":"OG000","title":"Pemetrexed + Erlotinib","description":"Pemetrexed 500 mg/m\\^2 of BSA, administered by IV infusion on Day 1 plus erlotinib 150 mg orally once daily on Day 2 through Day 14 of each 21-day cycle until disease progression or unacceptable toxicity developed or up to 38 months."},{"id":"OG001","title":"Erlotinib","description":"Erlotinib 150 mg, administered orally once daily in each 21-day cycle until disease progression or unacceptable toxicity developed or up to 38 months."},{"id":"OG002","title":"Pemetrexed","description":"Pemetrexed 500 mg/m\\^2 of BSA, administered by IV infusion on Day 1 of each 21-day cycle until progression or unacceptable toxicity developed or up to 38 months."}],"denoms":[{"units":"Participants","counts":[{"groupId":"OG000","value":"78"},{"groupId":"OG001","value":"83"},{"groupId":"OG002","value":"80"}]}],"classes":[{"title":"Serious Adverse Events","categories":[{"measurements":[{"groupId":"OG000","value":"25"},{"groupId":"OG001","value":"18"},{"groupId":"OG002","value":"22"}]}]},{"title":"Other Non-Serious Adverse Events","categories":[{"measurements":[{"groupId":"OG000","value":"72"},{"groupId":"OG001","value":"76"},{"groupId":"OG002","value":"67"}]}]}]},{"type":"SECONDARY","title":"Percentage of Participants With CR, PR, and Stable Disease (SD) - Disease Control Rate (DCR)","description":"DCR was defined as the percentage of participants with CR, PR, or SD divided by the number of randomized and treated participants as assessed using the RECIST criteria. CR was defined as the disappearance of all target lesions; PR was defined as 1) at least a 30% decrease in sum of longest diameter of target lesions or 2) complete disappearance of target lesions, with persistence (but not worsening) of 1 or more non-target lesions; PD was defined as at least a 20% increase in sum of longest diameter of target lesions; SD was defined as small changes that did not meet the above criteria.","populationDescription":"Q-ITT-TA Population: defined as all participants, with nonsquamous histology, who were randomized to therapy and had measurable or evaluable lesions at baseline.","reportingStatus":"POSTED","paramType":"NUMBER","unitOfMeasure":"percentage of participants","timeFrame":"Randomization to disease progression up to 38 months","groups":[{"id":"OG000","title":"Pemetrexed + Erlotinib","description":"Pemetrexed 500 mg/m\\^2 of body surface area, administered by IV infusion on Day 1 plus erlotinib 150 mg orally once daily on Day 2 through Day 14 of each 21-day cycle until disease progression or unacceptable toxicity developed or up to 38 months."},{"id":"OG001","title":"Erlotinib","description":"Erlotinib 150 mg, administered orally once daily in each 21-day cycle until disease progression or unacceptable toxicity developed or up to 38 months."},{"id":"OG002","title":"Pemetrexed","description":"Pemetrexed 500 mg/m\\^2 of BSA, administered by IV infusion on Day 1 of each 21-day cycle until progression or unacceptable toxicity developed or up to 38 months."}],"denoms":[{"units":"Participants","counts":[{"groupId":"OG000","value":"76"},{"groupId":"OG001","value":"82"},{"groupId":"OG002","value":"80"}]}],"classes":[{"categories":[{"measurements":[{"groupId":"OG000","value":"64.5"},{"groupId":"OG001","value":"52.4"},{"groupId":"OG002","value":"56.3"}]}]}],"analyses":[{"groupIds":["OG000","OG001","OG002"],"testedNonInferiority":false,"nonInferiorityType":"SUPERIORITY_OR_OTHER","pValue":"0.306","statisticalMethod":"Regression, Logistic","statisticalComment":"Model is adjusted to covariates ECOG PS (0/1 vs.2), histological subtype (adeno vs. non-adeno), race (East Asian and non-East Asian) and gender."},{"groupIds":["OG000","OG001"],"testedNonInferiority":false,"nonInferiorityType":"SUPERIORITY_OR_OTHER","pValue":"0.127","statisticalMethod":"Regression, Logistic","statisticalComment":"Model is adjusted to covariates ECOG PS (0/1 vs.2), histological subtype (adeno vs. non-adeno), race (East Asian and non-East Asian) and gender.","paramType":"Odds Ratio (OR)","paramValue":"1.66","ciPctValue":"95","ciNumSides":"TWO_SIDED","ciLowerLimit":"0.87","ciUpperLimit":"3.18"},{"groupIds":["OG000","OG002"],"testedNonInferiority":false,"nonInferiorityType":"SUPERIORITY_OR_OTHER","pValue":"0.318","statisticalMethod":"Regression, Logistic","statisticalComment":"Model is adjusted to covariates ECOG PS (0/1 vs.2), histological subtype (adeno vs. non-adeno), race (East Asian and non-East Asian) and gender.","paramType":"Odds Ratio (OR)","paramValue":"1.40","ciPctValue":"95","ciNumSides":"TWO_SIDED","ciLowerLimit":"0.72","ciUpperLimit":"2.71"},{"groupIds":["OG001","OG002"],"testedNonInferiority":false,"nonInferiorityType":"SUPERIORITY_OR_OTHER","pValue":"0.599","statisticalMethod":"Regression, Logistic","statisticalComment":"Model is adjusted to covariates ECOG PS (0/1 vs.2), histological subtype (adeno vs. non-adeno), race (East Asian and non-East Asian) and gender.","paramType":"Odds Ratio (OR)","paramValue":"1.18","ciPctValue":"95","ciNumSides":"TWO_SIDED","ciLowerLimit":"0.63","ciUpperLimit":"2.22"}]},{"type":"SECONDARY","title":"Time to Worsening of Symptoms (TWS) on Lung Cancer Symptoms Scale (LCSS)","description":"TWS assessed using the LCSS a participant rated lung cancer instrument which consisted of 9 disease related symptoms and quality of life (QoL) items, with 6 subscales related to major lung cancer symptoms (appetite, cough, fatigue, dyspnea, hemoptysis, and pain) and 3 summation items related to QoL (activity status, symptomatic distress, and overall QoL). Each item is marked on a visual analog scale (VAS) 0 (low symptoms/QoL items) to 100 (high symptoms/QoL items). The mean of the 6 subscales is used to calculate the average symptom burden index. TWS was measured from the date of study enrollment to the first date of a worsening in any 1 of the 6 LCSS symptom-specific items (as defined by a VAS 15-mm increase from baseline in the patient-reported score for any of these 6 items).","populationDescription":"A subset of the Q-ITT Population that included participants with LCSS results; Q-ITT Population: defined as all participants, with nonsquamous histology, who were randomized to therapy.","reportingStatus":"POSTED","paramType":"MEDIAN","dispersionType":"95% Confidence Interval","unitOfMeasure":"months","timeFrame":"Randomization to first date of worsening of any of 6 LCSS symptom specific items or up to 12.4 months","groups":[{"id":"OG000","title":"Pemetrexed + Erlotinib","description":"Pemetrexed 500 mg/m\\^2 of BSA, administered by IV infusion on Day 1 plus erlotinib 150 mg orally once daily on Day 2 through Day 14 of each 21-day cycle until disease progression or unacceptable toxicity developed or up to 38 months."},{"id":"OG001","title":"Erlotinib","description":"Erlotinib 150 mg, administered orally once daily in each 21-day cycle until disease progression or unacceptable toxicity developed or up to 38 months."},{"id":"OG002","title":"Pemetrexed","description":"Pemetrexed 500 mg/m\\^2 of BSA, administered by IV infusion on Day 1 of each 21-day cycle until progression or unacceptable toxicity developed or up to 38 months."}],"denoms":[{"units":"Participants","counts":[{"groupId":"OG000","value":"70"},{"groupId":"OG001","value":"71"},{"groupId":"OG002","value":"65"}]}],"classes":[{"categories":[{"measurements":[{"groupId":"OG000","value":"1.0","lowerLimit":"0.9","upperLimit":"1.6"},{"groupId":"OG001","value":"0.8","lowerLimit":"0.8","upperLimit":"1.2"},{"groupId":"OG002","value":"1.5","lowerLimit":"1.0","upperLimit":"2.1"}]}]}],"analyses":[{"groupIds":["OG000","OG001","OG002"],"testedNonInferiority":false,"nonInferiorityType":"SUPERIORITY_OR_OTHER","pValue":"0.013","statisticalMethod":"Regression, Cox","statisticalComment":"Model is adjusted to covariates ECOG PS (0/1 vs.2), histological subtype (adeno vs. non-adeno), race (East Asian and non-East Asian) and gender.","ciPctValue":"95"},{"groupIds":["OG000","OG001"],"testedNonInferiority":false,"nonInferiorityType":"SUPERIORITY_OR_OTHER","pValue":"0.007","pValueComment":"Model is adjusted to covariates ECOG PS (0/1 vs.2), histological subtype (adeno vs. non-adeno), race (East Asian and non-East Asian) and gender.","statisticalMethod":"Regression, Cox","statisticalComment":"Model is adjusted to covariates ECOG PS (0/1 vs.2), histological subtype (adeno vs. non-adeno), race (East Asian and non-East Asian) and gender.","paramType":"Hazard Ratio (HR)","paramValue":"0.59","ciPctValue":"95","ciNumSides":"TWO_SIDED","ciLowerLimit":"0.41","ciUpperLimit":"0.87"},{"groupIds":["OG000","OG002"],"testedNonInferiority":false,"nonInferiorityType":"SUPERIORITY_OR_OTHER","pValue":"0.700","statisticalMethod":"Regression, Cox","statisticalComment":"Model is adjusted to covariates ECOG PS (0/1 vs.2), histological subtype (adeno vs. non-adeno), race (East Asian and non-East Asian) and gender.","paramType":"Hazard Ratio (HR)","paramValue":"0.92","ciPctValue":"95","ciNumSides":"TWO_SIDED","ciLowerLimit":"0.62","ciUpperLimit":"1.38"},{"groupIds":["OG001","OG002"],"testedNonInferiority":false,"nonInferiorityType":"SUPERIORITY_OR_OTHER","pValue":"0.023","statisticalMethod":"Regression, Cox","statisticalComment":"Model is adjusted to covariates ECOG PS (0/1 vs.2), histological subtype (adeno vs. non-adeno), race (East Asian and non-East Asian) and gender.","paramType":"Hazard Ratio (HR)","paramValue":"0.64","ciPctValue":"95","ciNumSides":"TWO_SIDED","ciLowerLimit":"0.44","ciUpperLimit":"0.94"}]},{"type":"SECONDARY","title":"Number of Participants With Mutated or Non-Mutated Epidermal Growth Factor Receptor (EGFR) Genotype Status","description":"EGFR mutation status was defined as: participants with any mutations detected were categorized as mutated and participants without any mutations detected were categorized as non-mutated.","populationDescription":"A subset of the Q-ITT Population who had EGFR samples; Q-ITT Population: defined as all participants with nonsquamous histology, who were randomized to therapy.","reportingStatus":"POSTED","paramType":"NUMBER","unitOfMeasure":"participants","timeFrame":"Randomization to date of PD or death up to 38 months","groups":[{"id":"OG000","title":"Pemetrexed + Erlotinib","description":"Pemetrexed 500 mg/m\\^2 of BSA, administered by IV infusion on Day 1 plus erlotinib 150 mg orally once daily on Day 2 through Day 14 of each 21-day cycle until disease progression or unacceptable toxicity developed or up to 38 months."},{"id":"OG001","title":"Erlotinib","description":"Erlotinib 150 mg, administered orally once daily in each 21-day cycle until disease progression or unacceptable toxicity developed or up to 38 months."},{"id":"OG002","title":"Pemetrexed","description":"Pemetrexed 500 mg/m\\^2 of BSA, administered by IV infusion on Day 1 of each 21-day cycle until progression or unacceptable toxicity developed or up to 38 months."}],"denoms":[{"units":"Participants","counts":[{"groupId":"OG000","value":"22"},{"groupId":"OG001","value":"16"},{"groupId":"OG002","value":"15"}]}],"classes":[{"title":"Mutated","categories":[{"measurements":[{"groupId":"OG000","value":"7","lowerLimit":"7.1"},{"groupId":"OG001","value":"8"},{"groupId":"OG002","value":"9"}]}]},{"title":"Non-mutated","categories":[{"measurements":[{"groupId":"OG000","value":"10"},{"groupId":"OG001","value":"6"},{"groupId":"OG002","value":"3"}]}]},{"title":"Mutation status unknown (treated as missing)","categories":[{"measurements":[{"groupId":"OG000","value":"5"},{"groupId":"OG001","value":"2"},{"groupId":"OG002","value":"3"}]}]}],"analyses":[{"groupIds":["OG000","OG001","OG002"],"testedNonInferiority":false,"nonInferiorityType":"SUPERIORITY_OR_OTHER","pValue":"0.040","statisticalMethod":"Regression, Cox","ciPctValue":"95"},{"groupIds":["OG000","OG001"],"testedNonInferiority":false,"nonInferiorityType":"SUPERIORITY_OR_OTHER","pValue":"0.241","statisticalMethod":"Regression, Cox","paramType":"Hazard Ratio (HR)","paramValue":"0.62","ciPctValue":"95","ciNumSides":"TWO_SIDED","ciLowerLimit":"0.27","ciUpperLimit":"1.38"},{"groupIds":["OG000","OG002"],"testedNonInferiority":false,"nonInferiorityType":"SUPERIORITY_OR_OTHER","pValue":"0.011","statisticalMethod":"Regression, Cox","paramType":"Hazard Ratio (HR)","paramValue":"0.32","ciPctValue":"95","ciNumSides":"TWO_SIDED","ciLowerLimit":"0.14","ciUpperLimit":"0.78"},{"groupIds":["OG001","OG002"],"testedNonInferiority":false,"nonInferiorityType":"SUPERIORITY_OR_OTHER","pValue":"0.128","statisticalMethod":"Regression, Cox","paramType":"Hazard Ratio (HR)","paramValue":"1.90","ciPctValue":"95","ciNumSides":"TWO_SIDED","ciLowerLimit":"0.83","ciUpperLimit":"4.36"}]},{"type":"SECONDARY","title":"Probability of OS at 12 Months","description":"OS time is censored at the date of last contact for participants who were still alive or lost to follow-up.","populationDescription":"Q-ITT Population: defined as all participants with nonsquamous histology, who were randomized to therapy.","reportingStatus":"POSTED","paramType":"NUMBER","dispersionType":"95% Confidence Interval","unitOfMeasure":"percent chance of survival","timeFrame":"Month 12","groups":[{"id":"OG000","title":"Pemetrexed + Erlotinib","description":"Pemetrexed 500 mg/m\\^2 of BSA, administered by IV infusion on Day 1 plus erlotinib 150 mg orally once daily on Day 2 through Day 14 of each 21-day cycle until disease progression or unacceptable toxicity developed or up to 38 months."},{"id":"OG001","title":"Erlotinib","description":"Erlotinib 150 mg, administered orally once daily in each 21-day cycle until disease progression or unacceptable toxicity developed or up to 38 months."},{"id":"OG002","title":"Pemetrexed","description":"Pemetrexed 500 mg/m\\^2 of BSA, administered by IV infusion on Day 1 of each 21-day cycle until progression or unacceptable toxicity developed or up to 38 months."}],"denoms":[{"units":"Participants","counts":[{"groupId":"OG000","value":"78"},{"groupId":"OG001","value":"82"},{"groupId":"OG002","value":"80"}]}],"classes":[{"categories":[{"measurements":[{"groupId":"OG000","value":"40.2","lowerLimit":"28.3","upperLimit":"51.8"},{"groupId":"OG001","value":"26.2","lowerLimit":"17.2","upperLimit":"36.1"},{"groupId":"OG002","value":"18.1","lowerLimit":"9.1","upperLimit":"29.4"}]}]}]}]},"adverseEventsModule":{"frequencyThreshold":"5","description":"One participant was assigned to Pemetrexed (single therapy) but received Erlotinib (single therapy) at the first cycle, this leads to the discrepancy of participants for the safety analysis.","eventGroups":[{"id":"EG000","title":"Pemetrexed + Erlotinib","description":"Participants received pemetrexed 500 milligrams per meter squared (mg/m\\^2) of body surface area, administered by intravenous (IV) infusion on Day 1 plus erlotinib 150 mg orally once daily on Day 2 through Day 14 of each 21 day cycle until disease progression or unacceptable toxicity developed up to 39 months.","seriousNumAffected":25,"seriousNumAtRisk":78,"otherNumAffected":72,"otherNumAtRisk":78},{"id":"EG001","title":"Erlotinib","description":"Participants received erlotinib 150 mg, administered orally once daily in each 21 day cycle until disease progression or unacceptable toxicity developed up to 39 months.","seriousNumAffected":18,"seriousNumAtRisk":83,"otherNumAffected":76,"otherNumAtRisk":83},{"id":"EG002","title":"Pemetrexed","description":"Participants received pemetrexed 500 mg/m\\^2 of body surface area, administered by intravenous (IV) infusion on Day 1 of each 21 day cycle until progression or unacceptable toxicity developed up to 39 months.","seriousNumAffected":22,"seriousNumAtRisk":80,"otherNumAffected":67,"otherNumAtRisk":80}],"seriousEvents":[{"term":"Anaemia","organSystem":"Blood and lymphatic system disorders","sourceVocabulary":"MedDRA 14.1","assessmentType":"SYSTEMATIC_ASSESSMENT","stats":[{"groupId":"EG000","numEvents":0,"numAffected":0,"numAtRisk":78},{"groupId":"EG001","numEvents":0,"numAffected":0,"numAtRisk":83},{"groupId":"EG002","numEvents":1,"numAffected":1,"numAtRisk":80}]},{"term":"Febrile neutropenia","organSystem":"Blood and lymphatic system disorders","sourceVocabulary":"MedDRA 14.1","assessmentType":"SYSTEMATIC_ASSESSMENT","stats":[{"groupId":"EG000","numEvents":1,"numAffected":1,"numAtRisk":78},{"groupId":"EG001","numEvents":0,"numAffected":0,"numAtRisk":83},{"groupId":"EG002","numEvents":0,"numAffected":0,"numAtRisk":80}]},{"term":"Leukopenia","organSystem":"Blood and lymphatic system disorders","sourceVocabulary":"MedDRA 14.1","assessmentType":"SYSTEMATIC_ASSESSMENT","stats":[{"groupId":"EG000","numEvents":1,"numAffected":1,"numAtRisk":78},{"groupId":"EG001","numEvents":0,"numAffected":0,"numAtRisk":83},{"groupId":"EG002","numEvents":0,"numAffected":0,"numAtRisk":80}]},{"term":"Lymphopenia","organSystem":"Blood and lymphatic system disorders","sourceVocabulary":"MedDRA 14.1","assessmentType":"SYSTEMATIC_ASSESSMENT","stats":[{"groupId":"EG000","numEvents":1,"numAffected":1,"numAtRisk":78},{"groupId":"EG001","numEvents":0,"numAffected":0,"numAtRisk":83},{"groupId":"EG002","numEvents":1,"numAffected":1,"numAtRisk":80}]},{"term":"Neutropenia","organSystem":"Blood and lymphatic system disorders","sourceVocabulary":"MedDRA 14.1","assessmentType":"SYSTEMATIC_ASSESSMENT","stats":[{"groupId":"EG000","numEvents":0,"numAffected":0,"numAtRisk":78},{"groupId":"EG001","numEvents":0,"numAffected":0,"numAtRisk":83},{"groupId":"EG002","numEvents":3,"numAffected":3,"numAtRisk":80}]},{"term":"Thrombocytopenia","organSystem":"Blood and lymphatic system disorders","sourceVocabulary":"MedDRA 14.1","assessmentType":"SYSTEMATIC_ASSESSMENT","stats":[{"groupId":"EG000","numEvents":1,"numAffected":1,"numAtRisk":78},{"groupId":"EG001","numEvents":0,"numAffected":0,"numAtRisk":83},{"groupId":"EG002","numEvents":1,"numAffected":1,"numAtRisk":80}]},{"term":"Arrhythmia","organSystem":"Cardiac disorders","sourceVocabulary":"MedDRA 14.1","assessmentType":"SYSTEMATIC_ASSESSMENT","stats":[{"groupId":"EG000","numEvents":0,"numAffected":0,"numAtRisk":78},{"groupId":"EG001","numEvents":0,"numAffected":0,"numAtRisk":83},{"groupId":"EG002","numEvents":1,"numAffected":1,"numAtRisk":80}]},{"term":"Cardio-respiratory arrest","organSystem":"Cardiac disorders","sourceVocabulary":"MedDRA 14.1","assessmentType":"SYSTEMATIC_ASSESSMENT","stats":[{"groupId":"EG000","numEvents":1,"numAffected":1,"numAtRisk":78},{"groupId":"EG001","numEvents":0,"numAffected":0,"numAtRisk":83},{"groupId":"EG002","numEvents":0,"numAffected":0,"numAtRisk":80}]},{"term":"Myocardial infarction","organSystem":"Cardiac disorders","sourceVocabulary":"MedDRA 14.1","assessmentType":"SYSTEMATIC_ASSESSMENT","stats":[{"groupId":"EG000","numEvents":1,"numAffected":1,"numAtRisk":78},{"groupId":"EG001","numEvents":0,"numAffected":0,"numAtRisk":83},{"groupId":"EG002","numEvents":0,"numAffected":0,"numAtRisk":80}]},{"term":"Pericardial effusion","organSystem":"Cardiac disorders","sourceVocabulary":"MedDRA 14.1","assessmentType":"SYSTEMATIC_ASSESSMENT","stats":[{"groupId":"EG000","numEvents":0,"numAffected":0,"numAtRisk":78},{"groupId":"EG001","numEvents":0,"numAffected":0,"numAtRisk":83},{"groupId":"EG002","numEvents":1,"numAffected":1,"numAtRisk":80}]},{"term":"Vertigo positional","organSystem":"Ear and labyrinth disorders","sourceVocabulary":"MedDRA 14.1","assessmentType":"SYSTEMATIC_ASSESSMENT","stats":[{"groupId":"EG000","numEvents":0,"numAffected":0,"numAtRisk":78},{"groupId":"EG001","numEvents":0,"numAffected":0,"numAtRisk":83},{"groupId":"EG002","numEvents":1,"numAffected":1,"numAtRisk":80}]},{"term":"Abdominal pain","organSystem":"Gastrointestinal disorders","sourceVocabulary":"MedDRA 14.1","assessmentType":"SYSTEMATIC_ASSESSMENT","stats":[{"groupId":"EG000","numEvents":1,"numAffected":1,"numAtRisk":78},{"groupId":"EG001","numEvents":0,"numAffected":0,"numAtRisk":83},{"groupId":"EG002","numEvents":1,"numAffected":1,"numAtRisk":80}]},{"term":"Abdominal pain upper","organSystem":"Gastrointestinal disorders","sourceVocabulary":"MedDRA 14.1","assessmentType":"SYSTEMATIC_ASSESSMENT","stats":[{"groupId":"EG000","numEvents":1,"numAffected":1,"numAtRisk":78},{"groupId":"EG001","numEvents":0,"numAffected":0,"numAtRisk":83},{"groupId":"EG002","numEvents":0,"numAffected":0,"numAtRisk":80}]},{"term":"Constipation","organSystem":"Gastrointestinal disorders","sourceVocabulary":"MedDRA 14.1","assessmentType":"SYSTEMATIC_ASSESSMENT","stats":[{"groupId":"EG000","numEvents":0,"numAffected":0,"numAtRisk":78},{"groupId":"EG001","numEvents":0,"numAffected":0,"numAtRisk":83},{"groupId":"EG002","numEvents":1,"numAffected":1,"numAtRisk":80}]},{"term":"Diarrhoea","organSystem":"Gastrointestinal disorders","sourceVocabulary":"MedDRA 14.1","assessmentType":"SYSTEMATIC_ASSESSMENT","stats":[{"groupId":"EG000","numEvents":4,"numAffected":4,"numAtRisk":78},{"groupId":"EG001","numEvents":0,"numAffected":0,"numAtRisk":83},{"groupId":"EG002","numEvents":2,"numAffected":2,"numAtRisk":80}]},{"term":"Dyspepsia","organSystem":"Gastrointestinal disorders","sourceVocabulary":"MedDRA 14.1","assessmentType":"SYSTEMATIC_ASSESSMENT","stats":[{"groupId":"EG000","numEvents":0,"numAffected":0,"numAtRisk":78},{"groupId":"EG001","numEvents":1,"numAffected":1,"numAtRisk":83},{"groupId":"EG002","numEvents":0,"numAffected":0,"numAtRisk":80}]},{"term":"Gastric haemorrhage","organSystem":"Gastrointestinal disorders","sourceVocabulary":"MedDRA 14.1","assessmentType":"SYSTEMATIC_ASSESSMENT","stats":[{"groupId":"EG000","numEvents":1,"numAffected":1,"numAtRisk":78},{"groupId":"EG001","numEvents":0,"numAffected":0,"numAtRisk":83},{"groupId":"EG002","numEvents":0,"numAffected":0,"numAtRisk":80}]},{"term":"Gastric ulcer","organSystem":"Gastrointestinal disorders","sourceVocabulary":"MedDRA 14.1","assessmentType":"SYSTEMATIC_ASSESSMENT","stats":[{"groupId":"EG000","numEvents":0,"numAffected":0,"numAtRisk":78},{"groupId":"EG001","numEvents":1,"numAffected":1,"numAtRisk":83},{"groupId":"EG002","numEvents":0,"numAffected":0,"numAtRisk":80}]},{"term":"Gastritis","organSystem":"Gastrointestinal disorders","sourceVocabulary":"MedDRA 14.1","assessmentType":"SYSTEMATIC_ASSESSMENT","stats":[{"groupId":"EG000","numEvents":1,"numAffected":1,"numAtRisk":78},{"groupId":"EG001","numEvents":0,"numAffected":0,"numAtRisk":83},{"groupId":"EG002","numEvents":0,"numAffected":0,"numAtRisk":80}]},{"term":"Intestinal obstruction","organSystem":"Gastrointestinal disorders","sourceVocabulary":"MedDRA 14.1","assessmentType":"SYSTEMATIC_ASSESSMENT","stats":[{"groupId":"EG000","numEvents":1,"numAffected":1,"numAtRisk":78},{"groupId":"EG001","numEvents":0,"numAffected":0,"numAtRisk":83},{"groupId":"EG002","numEvents":0,"numAffected":0,"numAtRisk":80}]},{"term":"Nausea","organSystem":"Gastrointestinal disorders","sourceVocabulary":"MedDRA 14.1","assessmentType":"SYSTEMATIC_ASSESSMENT","stats":[{"groupId":"EG000","numEvents":0,"numAffected":0,"numAtRisk":78},{"groupId":"EG001","numEvents":0,"numAffected":0,"numAtRisk":83},{"groupId":"EG002","numEvents":1,"numAffected":1,"numAtRisk":80}]},{"term":"Stomatitis","organSystem":"Gastrointestinal disorders","sourceVocabulary":"MedDRA 14.1","assessmentType":"SYSTEMATIC_ASSESSMENT","stats":[{"groupId":"EG000","numEvents":1,"numAffected":1,"numAtRisk":78},{"groupId":"EG001","numEvents":1,"numAffected":1,"numAtRisk":83},{"groupId":"EG002","numEvents":0,"numAffected":0,"numAtRisk":80}]},{"term":"Vomiting","organSystem":"Gastrointestinal disorders","sourceVocabulary":"MedDRA 14.1","assessmentType":"SYSTEMATIC_ASSESSMENT","stats":[{"groupId":"EG000","numEvents":1,"numAffected":1,"numAtRisk":78},{"groupId":"EG001","numEvents":1,"numAffected":1,"numAtRisk":83},{"groupId":"EG002","numEvents":1,"numAffected":1,"numAtRisk":80}]},{"term":"Asthenia","organSystem":"General disorders","sourceVocabulary":"MedDRA 14.1","assessmentType":"SYSTEMATIC_ASSESSMENT","stats":[{"groupId":"EG000","numEvents":3,"numAffected":2,"numAtRisk":78},{"groupId":"EG001","numEvents":2,"numAffected":2,"numAtRisk":83},{"groupId":"EG002","numEvents":1,"numAffected":1,"numAtRisk":80}]},{"term":"Death","organSystem":"General disorders","sourceVocabulary":"MedDRA 14.1","assessmentType":"SYSTEMATIC_ASSESSMENT","stats":[{"groupId":"EG000","numEvents":0,"numAffected":0,"numAtRisk":78},{"groupId":"EG001","numEvents":0,"numAffected":0,"numAtRisk":83},{"groupId":"EG002","numEvents":1,"numAffected":1,"numAtRisk":80}]},{"term":"Irritability","organSystem":"General disorders","sourceVocabulary":"MedDRA 14.1","assessmentType":"SYSTEMATIC_ASSESSMENT","stats":[{"groupId":"EG000","numEvents":0,"numAffected":0,"numAtRisk":78},{"groupId":"EG001","numEvents":0,"numAffected":0,"numAtRisk":83},{"groupId":"EG002","numEvents":1,"numAffected":1,"numAtRisk":80}]},{"term":"Mucosal inflammation","organSystem":"General disorders","sourceVocabulary":"MedDRA 14.1","assessmentType":"SYSTEMATIC_ASSESSMENT","stats":[{"groupId":"EG000","numEvents":1,"numAffected":1,"numAtRisk":78},{"groupId":"EG001","numEvents":0,"numAffected":0,"numAtRisk":83},{"groupId":"EG002","numEvents":0,"numAffected":0,"numAtRisk":80}]},{"term":"Pyrexia","organSystem":"General disorders","sourceVocabulary":"MedDRA 14.1","assessmentType":"SYSTEMATIC_ASSESSMENT","stats":[{"groupId":"EG000","numEvents":3,"numAffected":3,"numAtRisk":78},{"groupId":"EG001","numEvents":2,"numAffected":2,"numAtRisk":83},{"groupId":"EG002","numEvents":1,"numAffected":1,"numAtRisk":80}]},{"term":"Sudden death","organSystem":"General disorders","sourceVocabulary":"MedDRA 14.1","assessmentType":"SYSTEMATIC_ASSESSMENT","stats":[{"groupId":"EG000","numEvents":0,"numAffected":0,"numAtRisk":78},{"groupId":"EG001","numEvents":1,"numAffected":1,"numAtRisk":83},{"groupId":"EG002","numEvents":1,"numAffected":1,"numAtRisk":80}]},{"term":"Hepatitis acute","organSystem":"Hepatobiliary disorders","sourceVocabulary":"MedDRA 14.1","assessmentType":"SYSTEMATIC_ASSESSMENT","stats":[{"groupId":"EG000","numEvents":0,"numAffected":0,"numAtRisk":78},{"groupId":"EG001","numEvents":0,"numAffected":0,"numAtRisk":83},{"groupId":"EG002","numEvents":1,"numAffected":1,"numAtRisk":80}]},{"term":"Hyperbilirubinaemia","organSystem":"Hepatobiliary disorders","sourceVocabulary":"MedDRA 14.1","assessmentType":"SYSTEMATIC_ASSESSMENT","stats":[{"groupId":"EG000","numEvents":0,"numAffected":0,"numAtRisk":78},{"groupId":"EG001","numEvents":0,"numAffected":0,"numAtRisk":83},{"groupId":"EG002","numEvents":1,"numAffected":1,"numAtRisk":80}]},{"term":"Abscess","organSystem":"Infections and infestations","sourceVocabulary":"MedDRA 14.1","assessmentType":"SYSTEMATIC_ASSESSMENT","stats":[{"groupId":"EG000","numEvents":0,"numAffected":0,"numAtRisk":78},{"groupId":"EG001","numEvents":1,"numAffected":1,"numAtRisk":83},{"groupId":"EG002","numEvents":0,"numAffected":0,"numAtRisk":80}]},{"term":"Bronchitis","organSystem":"Infections and infestations","sourceVocabulary":"MedDRA 14.1","assessmentType":"SYSTEMATIC_ASSESSMENT","stats":[{"groupId":"EG000","numEvents":0,"numAffected":0,"numAtRisk":78},{"groupId":"EG001","numEvents":1,"numAffected":1,"numAtRisk":83},{"groupId":"EG002","numEvents":0,"numAffected":0,"numAtRisk":80}]},{"term":"Device related infection","organSystem":"Infections and infestations","sourceVocabulary":"MedDRA 14.1","assessmentType":"SYSTEMATIC_ASSESSMENT","stats":[{"groupId":"EG000","numEvents":1,"numAffected":1,"numAtRisk":78},{"groupId":"EG001","numEvents":0,"numAffected":0,"numAtRisk":83},{"groupId":"EG002","numEvents":0,"numAffected":0,"numAtRisk":80}]},{"term":"Herpes zoster","organSystem":"Infections and infestations","sourceVocabulary":"MedDRA 14.1","assessmentType":"SYSTEMATIC_ASSESSMENT","stats":[{"groupId":"EG000","numEvents":0,"numAffected":0,"numAtRisk":78},{"groupId":"EG001","numEvents":0,"numAffected":0,"numAtRisk":83},{"groupId":"EG002","numEvents":1,"numAffected":1,"numAtRisk":80}]},{"term":"Lower respiratory tract infection","organSystem":"Infections and infestations","sourceVocabulary":"MedDRA 14.1","assessmentType":"SYSTEMATIC_ASSESSMENT","stats":[{"groupId":"EG000","numEvents":1,"numAffected":1,"numAtRisk":78},{"groupId":"EG001","numEvents":0,"numAffected":0,"numAtRisk":83},{"groupId":"EG002","numEvents":1,"numAffected":1,"numAtRisk":80}]},{"term":"Pneumonia","organSystem":"Infections and infestations","sourceVocabulary":"MedDRA 14.1","assessmentType":"SYSTEMATIC_ASSESSMENT","stats":[{"groupId":"EG000","numEvents":2,"numAffected":2,"numAtRisk":78},{"groupId":"EG001","numEvents":1,"numAffected":1,"numAtRisk":83},{"groupId":"EG002","numEvents":1,"numAffected":1,"numAtRisk":80}]},{"term":"Pneumonia bacterial","organSystem":"Infections and infestations","sourceVocabulary":"MedDRA 14.1","assessmentType":"SYSTEMATIC_ASSESSMENT","stats":[{"groupId":"EG000","numEvents":0,"numAffected":0,"numAtRisk":78},{"groupId":"EG001","numEvents":1,"numAffected":1,"numAtRisk":83},{"groupId":"EG002","numEvents":0,"numAffected":0,"numAtRisk":80}]},{"term":"Respiratory tract infection","organSystem":"Infections and infestations","sourceVocabulary":"MedDRA 14.1","assessmentType":"SYSTEMATIC_ASSESSMENT","stats":[{"groupId":"EG000","numEvents":0,"numAffected":0,"numAtRisk":78},{"groupId":"EG001","numEvents":4,"numAffected":3,"numAtRisk":83},{"groupId":"EG002","numEvents":0,"numAffected":0,"numAtRisk":80}]},{"term":"Respiratory tract infection bacterial","organSystem":"Infections and infestations","sourceVocabulary":"MedDRA 14.1","assessmentType":"SYSTEMATIC_ASSESSMENT","stats":[{"groupId":"EG000","numEvents":0,"numAffected":0,"numAtRisk":78},{"groupId":"EG001","numEvents":0,"numAffected":0,"numAtRisk":83},{"groupId":"EG002","numEvents":1,"numAffected":1,"numAtRisk":80}]},{"term":"Sepsis","organSystem":"Infections and infestations","sourceVocabulary":"MedDRA 14.1","assessmentType":"SYSTEMATIC_ASSESSMENT","stats":[{"groupId":"EG000","numEvents":2,"numAffected":2,"numAtRisk":78},{"groupId":"EG001","numEvents":0,"numAffected":0,"numAtRisk":83},{"groupId":"EG002","numEvents":1,"numAffected":1,"numAtRisk":80}]},{"term":"Subcutaneous abscess","organSystem":"Infections and infestations","sourceVocabulary":"MedDRA 14.1","assessmentType":"SYSTEMATIC_ASSESSMENT","stats":[{"groupId":"EG000","numEvents":0,"numAffected":0,"numAtRisk":78},{"groupId":"EG001","numEvents":1,"numAffected":1,"numAtRisk":83},{"groupId":"EG002","numEvents":0,"numAffected":0,"numAtRisk":80}]},{"term":"Urinary tract infection","organSystem":"Infections and infestations","sourceVocabulary":"MedDRA 14.1","assessmentType":"SYSTEMATIC_ASSESSMENT","stats":[{"groupId":"EG000","numEvents":1,"numAffected":1,"numAtRisk":78},{"groupId":"EG001","numEvents":1,"numAffected":1,"numAtRisk":83},{"groupId":"EG002","numEvents":0,"numAffected":0,"numAtRisk":80}]},{"term":"Spinal compression fracture","organSystem":"Injury, poisoning and procedural complications","sourceVocabulary":"MedDRA 14.1","assessmentType":"SYSTEMATIC_ASSESSMENT","stats":[{"groupId":"EG000","numEvents":0,"numAffected":0,"numAtRisk":78},{"groupId":"EG001","numEvents":1,"numAffected":1,"numAtRisk":83},{"groupId":"EG002","numEvents":0,"numAffected":0,"numAtRisk":80}]},{"term":"Thoracic vertebral fracture","organSystem":"Injury, poisoning and procedural complications","sourceVocabulary":"MedDRA 14.1","assessmentType":"SYSTEMATIC_ASSESSMENT","stats":[{"groupId":"EG000","numEvents":2,"numAffected":1,"numAtRisk":78},{"groupId":"EG001","numEvents":0,"numAffected":0,"numAtRisk":83},{"groupId":"EG002","numEvents":0,"numAffected":0,"numAtRisk":80}]},{"term":"Haemoglobin decreased","organSystem":"Investigations","sourceVocabulary":"MedDRA 14.1","assessmentType":"SYSTEMATIC_ASSESSMENT","stats":[{"groupId":"EG000","numEvents":1,"numAffected":1,"numAtRisk":78},{"groupId":"EG001","numEvents":0,"numAffected":0,"numAtRisk":83},{"groupId":"EG002","numEvents":1,"numAffected":1,"numAtRisk":80}]},{"term":"White blood cell count decreased","organSystem":"Investigations","sourceVocabulary":"MedDRA 14.1","assessmentType":"SYSTEMATIC_ASSESSMENT","stats":[{"groupId":"EG000","numEvents":0,"numAffected":0,"numAtRisk":78},{"groupId":"EG001","numEvents":0,"numAffected":0,"numAtRisk":83},{"groupId":"EG002","numEvents":1,"numAffected":1,"numAtRisk":80}]},{"term":"Decreased appetite","organSystem":"Metabolism and nutrition disorders","sourceVocabulary":"MedDRA 14.1","assessmentType":"SYSTEMATIC_ASSESSMENT","stats":[{"groupId":"EG000","numEvents":1,"numAffected":1,"numAtRisk":78},{"groupId":"EG001","numEvents":0,"numAffected":0,"numAtRisk":83},{"groupId":"EG002","numEvents":0,"numAffected":0,"numAtRisk":80}]},{"term":"Dehydration","organSystem":"Metabolism and nutrition disorders","sourceVocabulary":"MedDRA 14.1","assessmentType":"SYSTEMATIC_ASSESSMENT","stats":[{"groupId":"EG000","numEvents":0,"numAffected":0,"numAtRisk":78},{"groupId":"EG001","numEvents":0,"numAffected":0,"numAtRisk":83},{"groupId":"EG002","numEvents":1,"numAffected":1,"numAtRisk":80}]},{"term":"Hypocalcaemia","organSystem":"Metabolism and nutrition disorders","sourceVocabulary":"MedDRA 14.1","assessmentType":"SYSTEMATIC_ASSESSMENT","stats":[{"groupId":"EG000","numEvents":1,"numAffected":1,"numAtRisk":78},{"groupId":"EG001","numEvents":1,"numAffected":1,"numAtRisk":83},{"groupId":"EG002","numEvents":1,"numAffected":1,"numAtRisk":80}]},{"term":"Hypokalaemia","organSystem":"Metabolism and nutrition disorders","sourceVocabulary":"MedDRA 14.1","assessmentType":"SYSTEMATIC_ASSESSMENT","stats":[{"groupId":"EG000","numEvents":1,"numAffected":1,"numAtRisk":78},{"groupId":"EG001","numEvents":0,"numAffected":0,"numAtRisk":83},{"groupId":"EG002","numEvents":2,"numAffected":2,"numAtRisk":80}]},{"term":"Hypomagnesaemia","organSystem":"Metabolism and nutrition disorders","sourceVocabulary":"MedDRA 14.1","assessmentType":"SYSTEMATIC_ASSESSMENT","stats":[{"groupId":"EG000","numEvents":1,"numAffected":1,"numAtRisk":78},{"groupId":"EG001","numEvents":0,"numAffected":0,"numAtRisk":83},{"groupId":"EG002","numEvents":1,"numAffected":1,"numAtRisk":80}]},{"term":"Hyponatraemia","organSystem":"Metabolism and nutrition disorders","sourceVocabulary":"MedDRA 14.1","assessmentType":"SYSTEMATIC_ASSESSMENT","stats":[{"groupId":"EG000","numEvents":2,"numAffected":2,"numAtRisk":78},{"groupId":"EG001","numEvents":0,"numAffected":0,"numAtRisk":83},{"groupId":"EG002","numEvents":4,"numAffected":4,"numAtRisk":80}]},{"term":"Arthralgia","organSystem":"Musculoskeletal and connective tissue disorders","sourceVocabulary":"MedDRA 14.1","assessmentType":"SYSTEMATIC_ASSESSMENT","stats":[{"groupId":"EG000","numEvents":1,"numAffected":1,"numAtRisk":78},{"groupId":"EG001","numEvents":1,"numAffected":1,"numAtRisk":83},{"groupId":"EG002","numEvents":0,"numAffected":0,"numAtRisk":80}]},{"term":"Back pain","organSystem":"Musculoskeletal and connective tissue disorders","sourceVocabulary":"MedDRA 14.1","assessmentType":"SYSTEMATIC_ASSESSMENT","stats":[{"groupId":"EG000","numEvents":0,"numAffected":0,"numAtRisk":78},{"groupId":"EG001","numEvents":2,"numAffected":2,"numAtRisk":83},{"groupId":"EG002","numEvents":3,"numAffected":3,"numAtRisk":80}]},{"term":"Bone pain","organSystem":"Musculoskeletal and connective tissue disorders","sourceVocabulary":"MedDRA 14.1","assessmentType":"SYSTEMATIC_ASSESSMENT","stats":[{"groupId":"EG000","numEvents":1,"numAffected":1,"numAtRisk":78},{"groupId":"EG001","numEvents":0,"numAffected":0,"numAtRisk":83},{"groupId":"EG002","numEvents":0,"numAffected":0,"numAtRisk":80}]},{"term":"Intervertebral disc protrusion","organSystem":"Musculoskeletal and connective tissue disorders","sourceVocabulary":"MedDRA 14.1","assessmentType":"SYSTEMATIC_ASSESSMENT","stats":[{"groupId":"EG000","numEvents":1,"numAffected":1,"numAtRisk":78},{"groupId":"EG001","numEvents":0,"numAffected":0,"numAtRisk":83},{"groupId":"EG002","numEvents":0,"numAffected":0,"numAtRisk":80}]},{"term":"Myalgia","organSystem":"Musculoskeletal and connective tissue disorders","sourceVocabulary":"MedDRA 14.1","assessmentType":"SYSTEMATIC_ASSESSMENT","stats":[{"groupId":"EG000","numEvents":1,"numAffected":1,"numAtRisk":78},{"groupId":"EG001","numEvents":0,"numAffected":0,"numAtRisk":83},{"groupId":"EG002","numEvents":0,"numAffected":0,"numAtRisk":80}]},{"term":"Pain in extremity","organSystem":"Musculoskeletal and connective tissue disorders","sourceVocabulary":"MedDRA 14.1","assessmentType":"SYSTEMATIC_ASSESSMENT","stats":[{"groupId":"EG000","numEvents":0,"numAffected":0,"numAtRisk":78},{"groupId":"EG001","numEvents":1,"numAffected":1,"numAtRisk":83},{"groupId":"EG002","numEvents":1,"numAffected":1,"numAtRisk":80}]},{"term":"Spinal osteoarthritis","organSystem":"Musculoskeletal and connective tissue disorders","sourceVocabulary":"MedDRA 14.1","assessmentType":"SYSTEMATIC_ASSESSMENT","stats":[{"groupId":"EG000","numEvents":0,"numAffected":0,"numAtRisk":78},{"groupId":"EG001","numEvents":1,"numAffected":1,"numAtRisk":83},{"groupId":"EG002","numEvents":0,"numAffected":0,"numAtRisk":80}]},{"term":"Metastases to meninges","organSystem":"Neoplasms benign, malignant and unspecified (incl cysts and polyps)","sourceVocabulary":"MedDRA 14.1","assessmentType":"SYSTEMATIC_ASSESSMENT","stats":[{"groupId":"EG000","numEvents":1,"numAffected":1,"numAtRisk":78},{"groupId":"EG001","numEvents":0,"numAffected":0,"numAtRisk":83},{"groupId":"EG002","numEvents":0,"numAffected":0,"numAtRisk":80}]},{"term":"Metastatic pain","organSystem":"Neoplasms benign, malignant and unspecified (incl cysts and polyps)","sourceVocabulary":"MedDRA 14.1","assessmentType":"SYSTEMATIC_ASSESSMENT","stats":[{"groupId":"EG000","numEvents":0,"numAffected":0,"numAtRisk":78},{"groupId":"EG001","numEvents":0,"numAffected":0,"numAtRisk":83},{"groupId":"EG002","numEvents":1,"numAffected":1,"numAtRisk":80}]},{"term":"Dizziness","organSystem":"Nervous system disorders","sourceVocabulary":"MedDRA 14.1","assessmentType":"SYSTEMATIC_ASSESSMENT","stats":[{"groupId":"EG000","numEvents":0,"numAffected":0,"numAtRisk":78},{"groupId":"EG001","numEvents":1,"numAffected":1,"numAtRisk":83},{"groupId":"EG002","numEvents":0,"numAffected":0,"numAtRisk":80}]},{"term":"Hemiplegia","organSystem":"Nervous system disorders","sourceVocabulary":"MedDRA 14.1","assessmentType":"SYSTEMATIC_ASSESSMENT","stats":[{"groupId":"EG000","numEvents":0,"numAffected":0,"numAtRisk":78},{"groupId":"EG001","numEvents":0,"numAffected":0,"numAtRisk":83},{"groupId":"EG002","numEvents":1,"numAffected":1,"numAtRisk":80}]},{"term":"Nervous system disorder","organSystem":"Nervous system disorders","sourceVocabulary":"MedDRA 14.1","assessmentType":"SYSTEMATIC_ASSESSMENT","stats":[{"groupId":"EG000","numEvents":0,"numAffected":0,"numAtRisk":78},{"groupId":"EG001","numEvents":0,"numAffected":0,"numAtRisk":83},{"groupId":"EG002","numEvents":1,"numAffected":1,"numAtRisk":80}]},{"term":"Neurotoxicity","organSystem":"Nervous system disorders","sourceVocabulary":"MedDRA 14.1","assessmentType":"SYSTEMATIC_ASSESSMENT","stats":[{"groupId":"EG000","numEvents":1,"numAffected":1,"numAtRisk":78},{"groupId":"EG001","numEvents":0,"numAffected":0,"numAtRisk":83},{"groupId":"EG002","numEvents":0,"numAffected":0,"numAtRisk":80}]},{"term":"Radicular pain","organSystem":"Nervous system disorders","sourceVocabulary":"MedDRA 14.1","assessmentType":"SYSTEMATIC_ASSESSMENT","stats":[{"groupId":"EG000","numEvents":0,"numAffected":0,"numAtRisk":78},{"groupId":"EG001","numEvents":1,"numAffected":1,"numAtRisk":83},{"groupId":"EG002","numEvents":0,"numAffected":0,"numAtRisk":80}]},{"term":"Renal failure chronic","organSystem":"Renal and urinary disorders","sourceVocabulary":"MedDRA 14.1","assessmentType":"SYSTEMATIC_ASSESSMENT","stats":[{"groupId":"EG000","numEvents":0,"numAffected":0,"numAtRisk":78},{"groupId":"EG001","numEvents":0,"numAffected":0,"numAtRisk":83},{"groupId":"EG002","numEvents":1,"numAffected":1,"numAtRisk":80}]},{"term":"Acute respiratory distress syndrome","organSystem":"Respiratory, thoracic and mediastinal disorders","sourceVocabulary":"MedDRA 14.1","assessmentType":"SYSTEMATIC_ASSESSMENT","stats":[{"groupId":"EG000","numEvents":0,"numAffected":0,"numAtRisk":78},{"groupId":"EG001","numEvents":0,"numAffected":0,"numAtRisk":83},{"groupId":"EG002","numEvents":1,"numAffected":1,"numAtRisk":80}]},{"term":"Dyspnoea","organSystem":"Respiratory, thoracic and mediastinal disorders","sourceVocabulary":"MedDRA 14.1","assessmentType":"SYSTEMATIC_ASSESSMENT","stats":[{"groupId":"EG000","numEvents":2,"numAffected":2,"numAtRisk":78},{"groupId":"EG001","numEvents":6,"numAffected":6,"numAtRisk":83},{"groupId":"EG002","numEvents":1,"numAffected":1,"numAtRisk":80}]},{"term":"Interstitial lung disease","organSystem":"Respiratory, thoracic and mediastinal disorders","sourceVocabulary":"MedDRA 14.1","assessmentType":"SYSTEMATIC_ASSESSMENT","stats":[{"groupId":"EG000","numEvents":1,"numAffected":1,"numAtRisk":78},{"groupId":"EG001","numEvents":0,"numAffected":0,"numAtRisk":83},{"groupId":"EG002","numEvents":0,"numAffected":0,"numAtRisk":80}]},{"term":"Pleural effusion","organSystem":"Respiratory, thoracic and mediastinal disorders","sourceVocabulary":"MedDRA 14.1","assessmentType":"SYSTEMATIC_ASSESSMENT","stats":[{"groupId":"EG000","numEvents":2,"numAffected":2,"numAtRisk":78},{"groupId":"EG001","numEvents":0,"numAffected":0,"numAtRisk":83},{"groupId":"EG002","numEvents":0,"numAffected":0,"numAtRisk":80}]},{"term":"Pneumothorax","organSystem":"Respiratory, thoracic and mediastinal disorders","sourceVocabulary":"MedDRA 14.1","assessmentType":"SYSTEMATIC_ASSESSMENT","stats":[{"groupId":"EG000","numEvents":1,"numAffected":1,"numAtRisk":78},{"groupId":"EG001","numEvents":0,"numAffected":0,"numAtRisk":83},{"groupId":"EG002","numEvents":0,"numAffected":0,"numAtRisk":80}]},{"term":"Pulmonary embolism","organSystem":"Respiratory, thoracic and mediastinal disorders","sourceVocabulary":"MedDRA 14.1","assessmentType":"SYSTEMATIC_ASSESSMENT","stats":[{"groupId":"EG000","numEvents":1,"numAffected":1,"numAtRisk":78},{"groupId":"EG001","numEvents":0,"numAffected":0,"numAtRisk":83},{"groupId":"EG002","numEvents":0,"numAffected":0,"numAtRisk":80}]},{"term":"Respiratory failure","organSystem":"Respiratory, thoracic and mediastinal disorders","sourceVocabulary":"MedDRA 14.1","assessmentType":"SYSTEMATIC_ASSESSMENT","stats":[{"groupId":"EG000","numEvents":0,"numAffected":0,"numAtRisk":78},{"groupId":"EG001","numEvents":0,"numAffected":0,"numAtRisk":83},{"groupId":"EG002","numEvents":2,"numAffected":2,"numAtRisk":80}]},{"term":"Dry skin","organSystem":"Skin and subcutaneous tissue disorders","sourceVocabulary":"MedDRA 14.1","assessmentType":"SYSTEMATIC_ASSESSMENT","stats":[{"groupId":"EG000","numEvents":0,"numAffected":0,"numAtRisk":78},{"groupId":"EG001","numEvents":1,"numAffected":1,"numAtRisk":83},{"groupId":"EG002","numEvents":0,"numAffected":0,"numAtRisk":80}]},{"term":"Rash","organSystem":"Skin and subcutaneous tissue disorders","sourceVocabulary":"MedDRA 14.1","assessmentType":"SYSTEMATIC_ASSESSMENT","stats":[{"groupId":"EG000","numEvents":0,"numAffected":0,"numAtRisk":78},{"groupId":"EG001","numEvents":1,"numAffected":1,"numAtRisk":83},{"groupId":"EG002","numEvents":0,"numAffected":0,"numAtRisk":80}]},{"term":"Skin hyperpigmentation","organSystem":"Skin and subcutaneous tissue disorders","sourceVocabulary":"MedDRA 14.1","assessmentType":"SYSTEMATIC_ASSESSMENT","stats":[{"groupId":"EG000","numEvents":0,"numAffected":0,"numAtRisk":78},{"groupId":"EG001","numEvents":0,"numAffected":0,"numAtRisk":83},{"groupId":"EG002","numEvents":1,"numAffected":1,"numAtRisk":80}]},{"term":"Hypertension","organSystem":"Vascular disorders","sourceVocabulary":"MedDRA 14.1","assessmentType":"SYSTEMATIC_ASSESSMENT","stats":[{"groupId":"EG000","numEvents":0,"numAffected":0,"numAtRisk":78},{"groupId":"EG001","numEvents":0,"numAffected":0,"numAtRisk":83},{"groupId":"EG002","numEvents":1,"numAffected":1,"numAtRisk":80}]},{"term":"Hypotension","organSystem":"Vascular disorders","sourceVocabulary":"MedDRA 14.1","assessmentType":"SYSTEMATIC_ASSESSMENT","stats":[{"groupId":"EG000","numEvents":0,"numAffected":0,"numAtRisk":78},{"groupId":"EG001","numEvents":0,"numAffected":0,"numAtRisk":83},{"groupId":"EG002","numEvents":1,"numAffected":1,"numAtRisk":80}]}],"otherEvents":[{"term":"Anaemia","organSystem":"Blood and lymphatic system disorders","sourceVocabulary":"MedDRA 14.1","assessmentType":"SYSTEMATIC_ASSESSMENT","stats":[{"groupId":"EG000","numEvents":14,"numAffected":11,"numAtRisk":78},{"groupId":"EG001","numEvents":5,"numAffected":3,"numAtRisk":83},{"groupId":"EG002","numEvents":9,"numAffected":7,"numAtRisk":80}]},{"term":"Leukopenia","organSystem":"Blood and lymphatic system disorders","sourceVocabulary":"MedDRA 14.1","assessmentType":"SYSTEMATIC_ASSESSMENT","stats":[{"groupId":"EG000","numEvents":27,"numAffected":6,"numAtRisk":78},{"groupId":"EG001","numEvents":0,"numAffected":0,"numAtRisk":83},{"groupId":"EG002","numEvents":13,"numAffected":5,"numAtRisk":80}]},{"term":"Lymphopenia","organSystem":"Blood and lymphatic system disorders","sourceVocabulary":"MedDRA 14.1","assessmentType":"SYSTEMATIC_ASSESSMENT","stats":[{"groupId":"EG000","numEvents":26,"numAffected":14,"numAtRisk":78},{"groupId":"EG001","numEvents":2,"numAffected":2,"numAtRisk":83},{"groupId":"EG002","numEvents":21,"numAffected":8,"numAtRisk":80}]},{"term":"Neutropenia","organSystem":"Blood and lymphatic system disorders","sourceVocabulary":"MedDRA 14.1","assessmentType":"SYSTEMATIC_ASSESSMENT","stats":[{"groupId":"EG000","numEvents":87,"numAffected":12,"numAtRisk":78},{"groupId":"EG001","numEvents":0,"numAffected":0,"numAtRisk":83},{"groupId":"EG002","numEvents":30,"numAffected":7,"numAtRisk":80}]},{"term":"Blepharitis","organSystem":"Eye disorders","sourceVocabulary":"MedDRA 14.1","assessmentType":"SYSTEMATIC_ASSESSMENT","stats":[{"groupId":"EG000","numEvents":4,"numAffected":4,"numAtRisk":78},{"groupId":"EG001","numEvents":16,"numAffected":11,"numAtRisk":83},{"groupId":"EG002","numEvents":0,"numAffected":0,"numAtRisk":80}]},{"term":"Conjunctivitis","organSystem":"Eye disorders","sourceVocabulary":"MedDRA 14.1","assessmentType":"SYSTEMATIC_ASSESSMENT","stats":[{"groupId":"EG000","numEvents":5,"numAffected":4,"numAtRisk":78},{"groupId":"EG001","numEvents":1,"numAffected":1,"numAtRisk":83},{"groupId":"EG002","numEvents":1,"numAffected":1,"numAtRisk":80}]},{"term":"Lacrimation increased","organSystem":"Eye disorders","sourceVocabulary":"MedDRA 14.1","assessmentType":"SYSTEMATIC_ASSESSMENT","stats":[{"groupId":"EG000","numEvents":5,"numAffected":4,"numAtRisk":78},{"groupId":"EG001","numEvents":4,"numAffected":4,"numAtRisk":83},{"groupId":"EG002","numEvents":4,"numAffected":4,"numAtRisk":80}]},{"term":"Vision blurred","organSystem":"Eye disorders","sourceVocabulary":"MedDRA 14.1","assessmentType":"SYSTEMATIC_ASSESSMENT","stats":[{"groupId":"EG000","numEvents":1,"numAffected":1,"numAtRisk":78},{"groupId":"EG001","numEvents":6,"numAffected":5,"numAtRisk":83},{"groupId":"EG002","numEvents":1,"numAffected":1,"numAtRisk":80}]},{"term":"Abdominal pain","organSystem":"Gastrointestinal disorders","sourceVocabulary":"MedDRA 14.1","assessmentType":"SYSTEMATIC_ASSESSMENT","stats":[{"groupId":"EG000","numEvents":11,"numAffected":5,"numAtRisk":78},{"groupId":"EG001","numEvents":5,"numAffected":5,"numAtRisk":83},{"groupId":"EG002","numEvents":3,"numAffected":3,"numAtRisk":80}]},{"term":"Abdominal pain upper","organSystem":"Gastrointestinal disorders","sourceVocabulary":"MedDRA 14.1","assessmentType":"SYSTEMATIC_ASSESSMENT","stats":[{"groupId":"EG000","numEvents":9,"numAffected":6,"numAtRisk":78},{"groupId":"EG001","numEvents":20,"numAffected":11,"numAtRisk":83},{"groupId":"EG002","numEvents":6,"numAffected":6,"numAtRisk":80}]},{"term":"Constipation","organSystem":"Gastrointestinal disorders","sourceVocabulary":"MedDRA 14.1","assessmentType":"SYSTEMATIC_ASSESSMENT","stats":[{"groupId":"EG000","numEvents":14,"numAffected":10,"numAtRisk":78},{"groupId":"EG001","numEvents":9,"numAffected":7,"numAtRisk":83},{"groupId":"EG002","numEvents":10,"numAffected":8,"numAtRisk":80}]},{"term":"Diarrhoea","organSystem":"Gastrointestinal disorders","sourceVocabulary":"MedDRA 14.1","assessmentType":"SYSTEMATIC_ASSESSMENT","stats":[{"groupId":"EG000","numEvents":65,"numAffected":29,"numAtRisk":78},{"groupId":"EG001","numEvents":70,"numAffected":29,"numAtRisk":83},{"groupId":"EG002","numEvents":10,"numAffected":8,"numAtRisk":80}]},{"term":"Dyspepsia","organSystem":"Gastrointestinal disorders","sourceVocabulary":"MedDRA 14.1","assessmentType":"SYSTEMATIC_ASSESSMENT","stats":[{"groupId":"EG000","numEvents":6,"numAffected":5,"numAtRisk":78},{"groupId":"EG001","numEvents":11,"numAffected":7,"numAtRisk":83},{"groupId":"EG002","numEvents":6,"numAffected":5,"numAtRisk":80}]},{"term":"Mouth ulceration","organSystem":"Gastrointestinal disorders","sourceVocabulary":"MedDRA 14.1","assessmentType":"SYSTEMATIC_ASSESSMENT","stats":[{"groupId":"EG000","numEvents":8,"numAffected":4,"numAtRisk":78},{"groupId":"EG001","numEvents":8,"numAffected":6,"numAtRisk":83},{"groupId":"EG002","numEvents":1,"numAffected":1,"numAtRisk":80}]},{"term":"Nausea","organSystem":"Gastrointestinal disorders","sourceVocabulary":"MedDRA 14.1","assessmentType":"SYSTEMATIC_ASSESSMENT","stats":[{"groupId":"EG000","numEvents":40,"numAffected":21,"numAtRisk":78},{"groupId":"EG001","numEvents":11,"numAffected":10,"numAtRisk":83},{"groupId":"EG002","numEvents":24,"numAffected":17,"numAtRisk":80}]},{"term":"Stomatitis","organSystem":"Gastrointestinal disorders","sourceVocabulary":"MedDRA 14.1","assessmentType":"SYSTEMATIC_ASSESSMENT","stats":[{"groupId":"EG000","numEvents":49,"numAffected":15,"numAtRisk":78},{"groupId":"EG001","numEvents":15,"numAffected":9,"numAtRisk":83},{"groupId":"EG002","numEvents":1,"numAffected":1,"numAtRisk":80}]},{"term":"Vomiting","organSystem":"Gastrointestinal disorders","sourceVocabulary":"MedDRA 14.1","assessmentType":"SYSTEMATIC_ASSESSMENT","stats":[{"groupId":"EG000","numEvents":37,"numAffected":25,"numAtRisk":78},{"groupId":"EG001","numEvents":11,"numAffected":10,"numAtRisk":83},{"groupId":"EG002","numEvents":14,"numAffected":12,"numAtRisk":80}]},{"term":"Asthenia","organSystem":"General disorders","sourceVocabulary":"MedDRA 14.1","assessmentType":"SYSTEMATIC_ASSESSMENT","stats":[{"groupId":"EG000","numEvents":16,"numAffected":12,"numAtRisk":78},{"groupId":"EG001","numEvents":7,"numAffected":6,"numAtRisk":83},{"groupId":"EG002","numEvents":22,"numAffected":6,"numAtRisk":80}]},{"term":"Chest pain","organSystem":"General disorders","sourceVocabulary":"MedDRA 14.1","assessmentType":"SYSTEMATIC_ASSESSMENT","stats":[{"groupId":"EG000","numEvents":4,"numAffected":4,"numAtRisk":78},{"groupId":"EG001","numEvents":12,"numAffected":12,"numAtRisk":83},{"groupId":"EG002","numEvents":3,"numAffected":3,"numAtRisk":80}]},{"term":"Fatigue","organSystem":"General disorders","sourceVocabulary":"MedDRA 14.1","assessmentType":"SYSTEMATIC_ASSESSMENT","stats":[{"groupId":"EG000","numEvents":33,"numAffected":20,"numAtRisk":78},{"groupId":"EG001","numEvents":11,"numAffected":9,"numAtRisk":83},{"groupId":"EG002","numEvents":24,"numAffected":17,"numAtRisk":80}]},{"term":"Mucosal inflammation","organSystem":"General disorders","sourceVocabulary":"MedDRA 14.1","assessmentType":"SYSTEMATIC_ASSESSMENT","stats":[{"groupId":"EG000","numEvents":27,"numAffected":14,"numAtRisk":78},{"groupId":"EG001","numEvents":8,"numAffected":7,"numAtRisk":83},{"groupId":"EG002","numEvents":5,"numAffected":3,"numAtRisk":80}]},{"term":"Oedema","organSystem":"General disorders","sourceVocabulary":"MedDRA 14.1","assessmentType":"SYSTEMATIC_ASSESSMENT","stats":[{"groupId":"EG000","numEvents":3,"numAffected":3,"numAtRisk":78},{"groupId":"EG001","numEvents":1,"numAffected":1,"numAtRisk":83},{"groupId":"EG002","numEvents":4,"numAffected":4,"numAtRisk":80}]},{"term":"Oedema peripheral","organSystem":"General disorders","sourceVocabulary":"MedDRA 14.1","assessmentType":"SYSTEMATIC_ASSESSMENT","stats":[{"groupId":"EG000","numEvents":24,"numAffected":8,"numAtRisk":78},{"groupId":"EG001","numEvents":1,"numAffected":1,"numAtRisk":83},{"groupId":"EG002","numEvents":7,"numAffected":6,"numAtRisk":80}]},{"term":"Pyrexia","organSystem":"General disorders","sourceVocabulary":"MedDRA 14.1","assessmentType":"SYSTEMATIC_ASSESSMENT","stats":[{"groupId":"EG000","numEvents":21,"numAffected":11,"numAtRisk":78},{"groupId":"EG001","numEvents":4,"numAffected":3,"numAtRisk":83},{"groupId":"EG002","numEvents":14,"numAffected":9,"numAtRisk":80}]},{"term":"Herpes zoster","organSystem":"Infections and infestations","sourceVocabulary":"MedDRA 14.1","assessmentType":"SYSTEMATIC_ASSESSMENT","stats":[{"groupId":"EG000","numEvents":5,"numAffected":5,"numAtRisk":78},{"groupId":"EG001","numEvents":1,"numAffected":1,"numAtRisk":83},{"groupId":"EG002","numEvents":2,"numAffected":2,"numAtRisk":80}]},{"term":"Paronychia","organSystem":"Infections and infestations","sourceVocabulary":"MedDRA 14.1","assessmentType":"SYSTEMATIC_ASSESSMENT","stats":[{"groupId":"EG000","numEvents":11,"numAffected":7,"numAtRisk":78},{"groupId":"EG001","numEvents":16,"numAffected":14,"numAtRisk":83},{"groupId":"EG002","numEvents":0,"numAffected":0,"numAtRisk":80}]},{"term":"Upper respiratory tract infection","organSystem":"Infections and infestations","sourceVocabulary":"MedDRA 14.1","assessmentType":"SYSTEMATIC_ASSESSMENT","stats":[{"groupId":"EG000","numEvents":10,"numAffected":7,"numAtRisk":78},{"groupId":"EG001","numEvents":8,"numAffected":4,"numAtRisk":83},{"groupId":"EG002","numEvents":3,"numAffected":3,"numAtRisk":80}]},{"term":"Urinary tract infection","organSystem":"Infections and infestations","sourceVocabulary":"MedDRA 14.1","assessmentType":"SYSTEMATIC_ASSESSMENT","stats":[{"groupId":"EG000","numEvents":5,"numAffected":4,"numAtRisk":78},{"groupId":"EG001","numEvents":1,"numAffected":1,"numAtRisk":83},{"groupId":"EG002","numEvents":1,"numAffected":1,"numAtRisk":80}]},{"term":"Alanine aminotransferase increased","organSystem":"Investigations","sourceVocabulary":"MedDRA 14.1","assessmentType":"SYSTEMATIC_ASSESSMENT","stats":[{"groupId":"EG000","numEvents":19,"numAffected":13,"numAtRisk":78},{"groupId":"EG001","numEvents":1,"numAffected":1,"numAtRisk":83},{"groupId":"EG002","numEvents":9,"numAffected":8,"numAtRisk":80}]},{"term":"Aspartate aminotransferase increased","organSystem":"Investigations","sourceVocabulary":"MedDRA 14.1","assessmentType":"SYSTEMATIC_ASSESSMENT","stats":[{"groupId":"EG000","numEvents":19,"numAffected":12,"numAtRisk":78},{"groupId":"EG001","numEvents":5,"numAffected":3,"numAtRisk":83},{"groupId":"EG002","numEvents":8,"numAffected":7,"numAtRisk":80}]},{"term":"Creatinine renal clearance decreased","organSystem":"Investigations","sourceVocabulary":"MedDRA 14.1","assessmentType":"SYSTEMATIC_ASSESSMENT","stats":[{"groupId":"EG000","numEvents":0,"numAffected":0,"numAtRisk":78},{"groupId":"EG001","numEvents":1,"numAffected":1,"numAtRisk":83},{"groupId":"EG002","numEvents":7,"numAffected":6,"numAtRisk":80}]},{"term":"Haemoglobin decreased","organSystem":"Investigations","sourceVocabulary":"MedDRA 14.1","assessmentType":"SYSTEMATIC_ASSESSMENT","stats":[{"groupId":"EG000","numEvents":21,"numAffected":10,"numAtRisk":78},{"groupId":"EG001","numEvents":13,"numAffected":4,"numAtRisk":83},{"groupId":"EG002","numEvents":7,"numAffected":5,"numAtRisk":80}]},{"term":"Neutrophil count decreased","organSystem":"Investigations","sourceVocabulary":"MedDRA 14.1","assessmentType":"SYSTEMATIC_ASSESSMENT","stats":[{"groupId":"EG000","numEvents":70,"numAffected":16,"numAtRisk":78},{"groupId":"EG001","numEvents":9,"numAffected":1,"numAtRisk":83},{"groupId":"EG002","numEvents":21,"numAffected":7,"numAtRisk":80}]},{"term":"Platelet count decreased","organSystem":"Investigations","sourceVocabulary":"MedDRA 14.1","assessmentType":"SYSTEMATIC_ASSESSMENT","stats":[{"groupId":"EG000","numEvents":11,"numAffected":6,"numAtRisk":78},{"groupId":"EG001","numEvents":0,"numAffected":0,"numAtRisk":83},{"groupId":"EG002","numEvents":20,"numAffected":5,"numAtRisk":80}]},{"term":"Weight decreased","organSystem":"Investigations","sourceVocabulary":"MedDRA 14.1","assessmentType":"SYSTEMATIC_ASSESSMENT","stats":[{"groupId":"EG000","numEvents":5,"numAffected":4,"numAtRisk":78},{"groupId":"EG001","numEvents":7,"numAffected":7,"numAtRisk":83},{"groupId":"EG002","numEvents":6,"numAffected":5,"numAtRisk":80}]},{"term":"White blood cell count decreased","organSystem":"Investigations","sourceVocabulary":"MedDRA 14.1","assessmentType":"SYSTEMATIC_ASSESSMENT","stats":[{"groupId":"EG000","numEvents":77,"numAffected":16,"numAtRisk":78},{"groupId":"EG001","numEvents":15,"numAffected":2,"numAtRisk":83},{"groupId":"EG002","numEvents":17,"numAffected":8,"numAtRisk":80}]},{"term":"Decreased appetite","organSystem":"Metabolism and nutrition disorders","sourceVocabulary":"MedDRA 14.1","assessmentType":"SYSTEMATIC_ASSESSMENT","stats":[{"groupId":"EG000","numEvents":39,"numAffected":23,"numAtRisk":78},{"groupId":"EG001","numEvents":24,"numAffected":15,"numAtRisk":83},{"groupId":"EG002","numEvents":31,"numAffected":19,"numAtRisk":80}]},{"term":"Hyperglycaemia","organSystem":"Metabolism and nutrition disorders","sourceVocabulary":"MedDRA 14.1","assessmentType":"SYSTEMATIC_ASSESSMENT","stats":[{"groupId":"EG000","numEvents":9,"numAffected":8,"numAtRisk":78},{"groupId":"EG001","numEvents":4,"numAffected":4,"numAtRisk":83},{"groupId":"EG002","numEvents":10,"numAffected":7,"numAtRisk":80}]},{"term":"Hyponatraemia","organSystem":"Metabolism and nutrition disorders","sourceVocabulary":"MedDRA 14.1","assessmentType":"SYSTEMATIC_ASSESSMENT","stats":[{"groupId":"EG000","numEvents":7,"numAffected":5,"numAtRisk":78},{"groupId":"EG001","numEvents":5,"numAffected":4,"numAtRisk":83},{"groupId":"EG002","numEvents":6,"numAffected":6,"numAtRisk":80}]},{"term":"Arthralgia","organSystem":"Musculoskeletal and connective tissue disorders","sourceVocabulary":"MedDRA 14.1","assessmentType":"SYSTEMATIC_ASSESSMENT","stats":[{"groupId":"EG000","numEvents":7,"numAffected":4,"numAtRisk":78},{"groupId":"EG001","numEvents":3,"numAffected":3,"numAtRisk":83},{"groupId":"EG002","numEvents":5,"numAffected":5,"numAtRisk":80}]},{"term":"Back pain","organSystem":"Musculoskeletal and connective tissue disorders","sourceVocabulary":"MedDRA 14.1","assessmentType":"SYSTEMATIC_ASSESSMENT","stats":[{"groupId":"EG000","numEvents":3,"numAffected":3,"numAtRisk":78},{"groupId":"EG001","numEvents":9,"numAffected":8,"numAtRisk":83},{"groupId":"EG002","numEvents":9,"numAffected":9,"numAtRisk":80}]},{"term":"Myalgia","organSystem":"Musculoskeletal and connective tissue disorders","sourceVocabulary":"MedDRA 14.1","assessmentType":"SYSTEMATIC_ASSESSMENT","stats":[{"groupId":"EG000","numEvents":7,"numAffected":4,"numAtRisk":78},{"groupId":"EG001","numEvents":5,"numAffected":3,"numAtRisk":83},{"groupId":"EG002","numEvents":6,"numAffected":3,"numAtRisk":80}]},{"term":"Pain in extremity","organSystem":"Musculoskeletal and connective tissue disorders","sourceVocabulary":"MedDRA 14.1","assessmentType":"SYSTEMATIC_ASSESSMENT","stats":[{"groupId":"EG000","numEvents":6,"numAffected":5,"numAtRisk":78},{"groupId":"EG001","numEvents":8,"numAffected":5,"numAtRisk":83},{"groupId":"EG002","numEvents":4,"numAffected":4,"numAtRisk":80}]},{"term":"Dizziness","organSystem":"Nervous system disorders","sourceVocabulary":"MedDRA 14.1","assessmentType":"SYSTEMATIC_ASSESSMENT","stats":[{"groupId":"EG000","numEvents":12,"numAffected":10,"numAtRisk":78},{"groupId":"EG001","numEvents":2,"numAffected":2,"numAtRisk":83},{"groupId":"EG002","numEvents":5,"numAffected":5,"numAtRisk":80}]},{"term":"Headache","organSystem":"Nervous system disorders","sourceVocabulary":"MedDRA 14.1","assessmentType":"SYSTEMATIC_ASSESSMENT","stats":[{"groupId":"EG000","numEvents":16,"numAffected":14,"numAtRisk":78},{"groupId":"EG001","numEvents":11,"numAffected":8,"numAtRisk":83},{"groupId":"EG002","numEvents":5,"numAffected":5,"numAtRisk":80}]},{"term":"Paraesthesia","organSystem":"Nervous system disorders","sourceVocabulary":"MedDRA 14.1","assessmentType":"SYSTEMATIC_ASSESSMENT","stats":[{"groupId":"EG000","numEvents":4,"numAffected":4,"numAtRisk":78},{"groupId":"EG001","numEvents":0,"numAffected":0,"numAtRisk":83},{"groupId":"EG002","numEvents":2,"numAffected":2,"numAtRisk":80}]},{"term":"Peripheral sensory neuropathy","organSystem":"Nervous system disorders","sourceVocabulary":"MedDRA 14.1","assessmentType":"SYSTEMATIC_ASSESSMENT","stats":[{"groupId":"EG000","numEvents":4,"numAffected":3,"numAtRisk":78},{"groupId":"EG001","numEvents":0,"numAffected":0,"numAtRisk":83},{"groupId":"EG002","numEvents":5,"numAffected":5,"numAtRisk":80}]},{"term":"Insomnia","organSystem":"Psychiatric disorders","sourceVocabulary":"MedDRA 14.1","assessmentType":"SYSTEMATIC_ASSESSMENT","stats":[{"groupId":"EG000","numEvents":18,"numAffected":10,"numAtRisk":78},{"groupId":"EG001","numEvents":14,"numAffected":10,"numAtRisk":83},{"groupId":"EG002","numEvents":6,"numAffected":5,"numAtRisk":80}]},{"term":"Cough","organSystem":"Respiratory, thoracic and mediastinal disorders","sourceVocabulary":"MedDRA 14.1","assessmentType":"SYSTEMATIC_ASSESSMENT","stats":[{"groupId":"EG000","numEvents":18,"numAffected":15,"numAtRisk":78},{"groupId":"EG001","numEvents":32,"numAffected":28,"numAtRisk":83},{"groupId":"EG002","numEvents":17,"numAffected":13,"numAtRisk":80}]},{"term":"Dyspnoea","organSystem":"Respiratory, thoracic and mediastinal disorders","sourceVocabulary":"MedDRA 14.1","assessmentType":"SYSTEMATIC_ASSESSMENT","stats":[{"groupId":"EG000","numEvents":12,"numAffected":10,"numAtRisk":78},{"groupId":"EG001","numEvents":10,"numAffected":10,"numAtRisk":83},{"groupId":"EG002","numEvents":10,"numAffected":10,"numAtRisk":80}]},{"term":"Haemoptysis","organSystem":"Respiratory, thoracic and mediastinal disorders","sourceVocabulary":"MedDRA 14.1","assessmentType":"SYSTEMATIC_ASSESSMENT","stats":[{"groupId":"EG000","numEvents":2,"numAffected":2,"numAtRisk":78},{"groupId":"EG001","numEvents":11,"numAffected":8,"numAtRisk":83},{"groupId":"EG002","numEvents":1,"numAffected":1,"numAtRisk":80}]},{"term":"Oropharyngeal pain","organSystem":"Respiratory, thoracic and mediastinal disorders","sourceVocabulary":"MedDRA 14.1","assessmentType":"SYSTEMATIC_ASSESSMENT","stats":[{"groupId":"EG000","numEvents":6,"numAffected":5,"numAtRisk":78},{"groupId":"EG001","numEvents":2,"numAffected":1,"numAtRisk":83},{"groupId":"EG002","numEvents":1,"numAffected":1,"numAtRisk":80}]},{"term":"Productive cough","organSystem":"Respiratory, thoracic and mediastinal disorders","sourceVocabulary":"MedDRA 14.1","assessmentType":"SYSTEMATIC_ASSESSMENT","stats":[{"groupId":"EG000","numEvents":7,"numAffected":5,"numAtRisk":78},{"groupId":"EG001","numEvents":7,"numAffected":6,"numAtRisk":83},{"groupId":"EG002","numEvents":2,"numAffected":2,"numAtRisk":80}]},{"term":"Rhinorrhoea","organSystem":"Respiratory, thoracic and mediastinal disorders","sourceVocabulary":"MedDRA 14.1","assessmentType":"SYSTEMATIC_ASSESSMENT","stats":[{"groupId":"EG000","numEvents":4,"numAffected":4,"numAtRisk":78},{"groupId":"EG001","numEvents":21,"numAffected":13,"numAtRisk":83},{"groupId":"EG002","numEvents":2,"numAffected":2,"numAtRisk":80}]},{"term":"Acne","organSystem":"Skin and subcutaneous tissue disorders","sourceVocabulary":"MedDRA 14.1","assessmentType":"SYSTEMATIC_ASSESSMENT","stats":[{"groupId":"EG000","numEvents":10,"numAffected":6,"numAtRisk":78},{"groupId":"EG001","numEvents":3,"numAffected":3,"numAtRisk":83},{"groupId":"EG002","numEvents":2,"numAffected":1,"numAtRisk":80}]},{"term":"Alopecia","organSystem":"Skin and subcutaneous tissue disorders","sourceVocabulary":"MedDRA 14.1","assessmentType":"SYSTEMATIC_ASSESSMENT","stats":[{"groupId":"EG000","numEvents":9,"numAffected":9,"numAtRisk":78},{"groupId":"EG001","numEvents":2,"numAffected":2,"numAtRisk":83},{"groupId":"EG002","numEvents":4,"numAffected":2,"numAtRisk":80}]},{"term":"Dermatitis acneiform","organSystem":"Skin and subcutaneous tissue disorders","sourceVocabulary":"MedDRA 14.1","assessmentType":"SYSTEMATIC_ASSESSMENT","stats":[{"groupId":"EG000","numEvents":19,"numAffected":10,"numAtRisk":78},{"groupId":"EG001","numEvents":5,"numAffected":5,"numAtRisk":83},{"groupId":"EG002","numEvents":2,"numAffected":1,"numAtRisk":80}]},{"term":"Dry skin","organSystem":"Skin and subcutaneous tissue disorders","sourceVocabulary":"MedDRA 14.1","assessmentType":"SYSTEMATIC_ASSESSMENT","stats":[{"groupId":"EG000","numEvents":15,"numAffected":12,"numAtRisk":78},{"groupId":"EG001","numEvents":26,"numAffected":25,"numAtRisk":83},{"groupId":"EG002","numEvents":2,"numAffected":2,"numAtRisk":80}]},{"term":"Nail disorder","organSystem":"Skin and subcutaneous tissue disorders","sourceVocabulary":"MedDRA 14.1","assessmentType":"SYSTEMATIC_ASSESSMENT","stats":[{"groupId":"EG000","numEvents":3,"numAffected":3,"numAtRisk":78},{"groupId":"EG001","numEvents":6,"numAffected":6,"numAtRisk":83},{"groupId":"EG002","numEvents":1,"numAffected":1,"numAtRisk":80}]},{"term":"Pruritus","organSystem":"Skin and subcutaneous tissue disorders","sourceVocabulary":"MedDRA 14.1","assessmentType":"SYSTEMATIC_ASSESSMENT","stats":[{"groupId":"EG000","numEvents":25,"numAffected":17,"numAtRisk":78},{"groupId":"EG001","numEvents":35,"numAffected":20,"numAtRisk":83},{"groupId":"EG002","numEvents":5,"numAffected":4,"numAtRisk":80}]},{"term":"Rash","organSystem":"Skin and subcutaneous tissue disorders","sourceVocabulary":"MedDRA 14.1","assessmentType":"SYSTEMATIC_ASSESSMENT","stats":[{"groupId":"EG000","numEvents":57,"numAffected":41,"numAtRisk":78},{"groupId":"EG001","numEvents":52,"numAffected":43,"numAtRisk":83},{"groupId":"EG002","numEvents":14,"numAffected":8,"numAtRisk":80}]},{"term":"Skin exfoliation","organSystem":"Skin and subcutaneous tissue disorders","sourceVocabulary":"MedDRA 14.1","assessmentType":"SYSTEMATIC_ASSESSMENT","stats":[{"groupId":"EG000","numEvents":5,"numAffected":5,"numAtRisk":78},{"groupId":"EG001","numEvents":14,"numAffected":12,"numAtRisk":83},{"groupId":"EG002","numEvents":0,"numAffected":0,"numAtRisk":80}]},{"term":"Skin hyperpigmentation","organSystem":"Skin and subcutaneous tissue disorders","sourceVocabulary":"MedDRA 14.1","assessmentType":"SYSTEMATIC_ASSESSMENT","stats":[{"groupId":"EG000","numEvents":0,"numAffected":0,"numAtRisk":78},{"groupId":"EG001","numEvents":2,"numAffected":2,"numAtRisk":83},{"groupId":"EG002","numEvents":6,"numAffected":6,"numAtRisk":80}]}]},"moreInfoModule":{"certainAgreement":{"piSponsorEmployee":false,"restrictionType":"GT60","restrictiveAgreement":true},"pointOfContact":{"title":"Chief Medical Officer","organization":"Eli Lilly and Company","phone":"800-545-5979"}}},"derivedSection":{"miscInfoModule":{"versionHolder":"2025-12-17","removedCountries":["Australia"]},"conditionBrowseModule":{"meshes":[{"id":"D002289","term":"Carcinoma, Non-Small-Cell Lung"}],"ancestors":[{"id":"D002283","term":"Carcinoma, Bronchogenic"},{"id":"D001984","term":"Bronchial Neoplasms"},{"id":"D008175","term":"Lung Neoplasms"},{"id":"D012142","term":"Respiratory Tract Neoplasms"},{"id":"D013899","term":"Thoracic Neoplasms"},{"id":"D009371","term":"Neoplasms by Site"},{"id":"D009369","term":"Neoplasms"},{"id":"D008171","term":"Lung Diseases"},{"id":"D012140","term":"Respiratory Tract Diseases"}]},"interventionBrowseModule":{"meshes":[{"id":"D000068437","term":"Pemetrexed"},{"id":"D000069347","term":"Erlotinib Hydrochloride"}],"ancestors":[{"id":"D006147","term":"Guanine"},{"id":"D007042","term":"Hypoxanthines"},{"id":"D011688","term":"Purinones"},{"id":"D011687","term":"Purines"},{"id":"D006574","term":"Heterocyclic Compounds, 2-Ring"},{"id":"D000072471","term":"Heterocyclic Compounds, Fused-Ring"},{"id":"D006571","term":"Heterocyclic Compounds"},{"id":"D005971","term":"Glutamates"},{"id":"D024342","term":"Amino Acids, Acidic"},{"id":"D000596","term":"Amino Acids"},{"id":"D000602","term":"Amino Acids, Peptides, and Proteins"},{"id":"D000600","term":"Amino Acids, Dicarboxylic"},{"id":"D011799","term":"Quinazolines"}]}},"hasResults":true}